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Abstract 
Quantitative structure-activity relationship study was performed to understand the activity 
of a set of 136 ligands of Translocator protein (TSPO) compounds. QSAR models were 
developed using multiple linear regression (MLR) as linear method. While principal 
component - artificial neural networks (PC-ANN) modeling method was used as nonlinear 
method. The results obtained offer good regression models having good prediction ability.  
The MLR resulted with models (12-24) which have coefficient of determination (R
2
)
 
>0.6, 
the best model (number 24) resulted with correlation coefficient (R) = 0.909, coefficient of 
determination (R
2
) = 0.826, and adjusted coefficient of determination (R
2
adj) = 0.788.  
Cross Validation leave one out (LOO) and leave many out (LMO) were performed on the 
resulted MLR models, models 19-24 showed a good predictive power. After that principle 
component analysis (PCA) performed to divide the data into three data sets, then the ANN 
performed on the chosen models (19-24) from leave one out (LOO) and leave many out 
(LMO) validation.  
ANN resulted models were validated through randomization test, then the conditions 
proposed by Golbraikh and Tropsha were applied to conclude that the QSAR models has 
acceptable prediction power or not. However the best ANN model with a good predictive 
power was model #24, with R test values 0.832. 
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1. Introduction: 
 
1.1 Overview of Computational Chemistry 
 
Recently, there have been ways to approach chemistry problems: non-computational 
quantum chemistry and computational quantum chemistry. 
Non-computational quantum chemistry deals with the formulation of analytical 
expressions for the properties of molecules and their reactions while computational 
quantum chemistry is primarily concerned with the numerical computation of molecular 
electronic structures. Thus In this research the Computational chemistry is used to solve 
the research problem [1]. 
Computational chemistry, alternatively sometimes called theoretical chemistry or 
molecular modeling. It is a field that can be said to be both old and young. It is old in the 
sense that its foundation was laid with the development of quantum mechanics in the early 
part of the twentieth century. However It is young, because computer technology has 
developed in the last 35 years or so [2]. 
The term computational chemistry is usually used when a mathematical method is 
sufficiently well developed that it can be automated for implementation on a computer. 
Thus, computational chemistry is the application of chemical, mathematical and computing 
skills by using computers in order to generate information such as properties of molecules 
or simulated experimental results to find the solution of interesting chemical problems [3]. 
Computational chemistry has become a useful way to investigate materials that are too 
difficult to find or too expensive to purchase. It also helps chemists make predictions 
before running the actual experiments so that they can be better prepared for making 
observations. 
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This branch of chemistry which generates data to complement experimental data on the 
structures, properties and reactions of substances [3]. Its calculations are based primarily 
on Schrödinger's equation (Equation 1-1) [4] and include: 
1. Calculation of electron and charge distributions 
2. Molecular geometry in ground and excited states 
3. Potential energy surfaces 
4. Rate constants for elementary reactions 
5. Details of the dynamics of molecular collisions 
HΨ = EΨ ……… (1-1) 
Where, H: Hamiltonian operator 
            Ψ: psi, the wave function 
            E: total energy of the system 
 
Therefore the helpful applications of computational chemistry have been widely utilized in 
the medicinal chemistry field. For example, it has allowed researchers to highlight the 
molecular basis of ligand-receptor interactions; define the pharmacophoric portion of 
known active ligands and the hindering regions of the inactive ones; build the three-
dimensional structure of the unresolved proteins using homology against a known 
template; design new ligands and predict their binding mode and affinities; and evaluate 
the crucial properties of compounds for their absorption, distribution, metabolism, and 
excretion. Indeed, all the steps of a medicinal chemistry workflow could be potentially 
realized in a virtual mode in silico, and if they are performed with competence and 
profitable criticism, they rationally guide the experimental phases of research and decrease 
productive costs. 
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The computational studies can give better results when many experimental data are 
available, providing a strong background for the calculations. Usually, the methodology 
has to be chosen on the basis of the amount and type of existing trial results in a certain 
topic: it could be ligand-based if only the information about known ligands and their 
activities on the target are used in the calculations as in this study or receptor-based if the 
three dimensional structure of the target is utilized to analyze the interaction with different 
ligands. If both kinds of experimental data are available, a robust computational procedure 
can be performed combining the ligand-based methods (like quantitative structure activity 
relationship (QSAR), 3DQSAR, and pharmacophoric studies) with receptor-based 
methods (like docking and its applications).  
1.2 Quantitative structure activity relationships (QSAR) 
 
  QSAR major goal is to formulate mathematical relationship between physico-chemical 
properties of compounds and their biological response in the system of interest, or with any 
other endpoint than the biological response such as chemical, physical and pharmaceutical 
properties. Hansch pioneered this field by demonstrating that the biological activities of 
drug molecules can be correlated to a few variables (Properties) using simple regression 
equation (Equation 1-2) [5], and after determination of this correlation there will be two 
expected outputs of the QSAR modeling; Firstly, enhance understanding of the specifics of 
drug action. Secondly, provide a theoretical foundation for future leading optimization. 
 
Log (1/C) = a (lipophilic descriptor) + b (Electronic descriptor) + c (Steric descriptor) + d 
(other descriptors) + etc.    …….. (1-2) 
 
Where,  
1/C = Measure of biological activity 
a, b, c, etc. = Regression coefficients 
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1.2.1 QSAR History 
 
More than a century ago, Crum-Brown and Fraser expressed the idea that the physiological 
action of a substance was a function of its chemical composition and constitution [6]. A 
few decades later, in 1893, Richet showed that the cytotoxicities of a diverse set of simple 
organic molecules were inversely related to their corresponding water solubility [7]. At the 
turn of the 20th century, Meyer and Overton independently suggested that the narcotic 
(depressant) action of a group of organic compounds paralleled their olive oil/water 
partition coefficients [8, 9]. In 1939 Ferguson introduced a thermodynamic generalization 
to the correlation of depressant action with the relative saturation of volatile compounds in 
the vehicle in which they were administered [10]. The extensive work of Albert, and Bell 
and Roblin established the acids in bacteriostatic activity [11, 12]. Meanwhile on the 
physical organic front, great strides were being made in the delineation of substituent 
effects on organic reactions, led by the seminal work of Hammett, which gave rise to 
―sigma-rho‖ [13]. Taft devised a way for separating polar, steric, and resonance effects and 
introducing the first steric parameter, ES. The contributions of Hammett and Taft together 
laid the mechanistic basis for the development of the QSAR paradigm by Hansch and 
Fujita. In 1962 Hansch and Muir published their brilliant study on the structure-activity 
relationships of plant growth regulators and their dependency on Hammett constants and 
hydrophobicity [14]. 
An early example of QSAR in drug design involves a series of 1-(X-phenyl)-3, 3-dialkyl 
triazenes. These compounds were of interest for their anti-tumor activity, but they also 
were mutagenic. QSAR was applied to understand how the structure might be modified to 
reduce the mutagenicity without significantly decreasing the anti-tumor activity. Based on 
equations it was observed that mutagenicity is more sensitive than anti-tumor activity to 
the electronic effects of the substituents. Thus, electron-withdrawing substituents were 
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examined by substituting a sulfonamide group at the para position, the anti-tumor activity 
was reduced 1.2-fold, whereas the mutagenicity was reduced by about 400-fold [15].  
    In the last ten years in Al-Quds computational chemistry laboratory, several QSAR 
studies have been applied to predict compounds properties, including biological activity, 
physical property, etc. [16-18]. 
1.2.2 QSAR advantages and disadvantages 
 
QSAR is important in drug development process. It provides quantitative relationship 
between structure and activity, in which help understanding the effect of structure on 
activity. It can also be used to help understand the interactions between functional groups 
in the molecules of greatest activity with those of their target. Bedsides, it helps in making 
predictions leading to the synthesis of novel analogous. Thus using QSAR in new drug 
development process decreases the cost of new drug development. 
On the other hand there is chance of false correlation between structure and activity; which 
may arise firstly because of biological data that came from a considerable experimental 
error. Secondly because of the dataset size; if it is not large enough, the data collected may 
not reflect the complete property space.  
Consequently, many QSAR results cannot be used to confidently predict the most likely 
compounds of best activity. However there are many successful applications but do not 
expect QSAR works all time [19, 20]. 
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1.3 QSAR model development steps 
 
QSAR model development process is typically performed in successive steps divided into 
three steps; Data preparation, data analysis, and model validation [21]:  
 
 
1.3.1 Data preparation 
 
Data preparation starts by selection of the data set to be used; which composed of 
compounds and their certain activity or any other endpoint, and this may simply be 
extracted from a database or may need additional experimental studies. And after that do a 
geometry optimization of the data set compounds; which is finding the coordinates that 
represents the minimum potential energy for the molecular structure in its 3D form, this 
can be done using software such as HyperChem which will be used in our study. 
Computational optimization encompasses a variety of mathematical methods which fall 
into two broad categories: 
• Molecular mechanics—applies the laws of classical physics to molecular nuclei without 
explicit consideration of electrons. 
• Quantum mechanics—relies on the Schrödinger equation to describe a molecule with 
explicit treatment of electronic structure. It is divided into two methods of calculations: 
  
1. Ab initio, the term is Latin for "from scratch". And it was first used by Robert Parr and 
coworkers.  Ab initio is a group of methods in which molecular structures can be 
calculated using nothing but the Schrödinger equation, the values of the fundamental 
constants and the atomic numbers of the atoms present. 
2. Semi-empirical techniques use approximations from empirical (experimental) data to   
provide the input into the mathematical models. And this method is preferred because 
it is faster than the ab initio method [22]. 
 8 
 
After geometry optimization using semi-empirical method in our study, the descriptors 
(properties) should be calculated using HyperChem and Dragon software. 
1.3.2 Data analysis 
 
The models building step in which a correlation between the endpoint and certain 
descriptors is determined. If the correlation models to be built are linear then the multi 
linear regression (MLR) is used, however if it is nonlinear then the artificial neural 
network (ANN) is performed after the MLR. 
Among the widely utilized algorithms applied for model construction in QSAR, in our 
study we will use multiple linear regression (MLR), and Principle Component artificial 
neural networks (PC-ANN).  
 
1.3.2.1 Linear Models 
 
 Multiple linear regression (MLR) 
 
MLR simultaneously considers the relationship between some independent variables and a 
dependent variable by fitting a linear equation to observed data. Generally, the multiple 
linear regression model represented in (Equation 1-3)  [23]: 
 
Yi = α + β1Xi,1 + · · · + βnXi,n + Ɛi  ……… (1-3) 
 
Where: 
α: is the intercept  
β1- βn: are slopes or coefficients of independent variables. 
Xi,1 – Xi,n : are independent variables. 
Ɛi: is the error term.  
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The MLR is the first statistical step that done because of the assumption that there is a 
linear correlation between the independent variables (descriptors) and the response variable 
(Y, Activity in our study). 
 
1.3.2.2 Nonlinear Models 
 
 Principal component analysis (PCA) 
 
Principal components analysis (PCA) also known as Eigenanalysis, is a statistical 
technique for analyzing data. Essentially, a set of correlated variables is transformed into a 
set of uncorrelated variables, which are ordered by reducing variability. The uncorrelated 
variables are linear combinations of the original variables, and the last of these variables 
can be removed with minimum loss of real data [24]. 
 
-       Artificial Neural Networks (ANN) 
 
Artiﬁcial neural network (ANN) analysis is a new method of data analysis, which inspired 
from the nervous system’s way of working in processing information [25]. The nervous 
system as brain has approximately 100 billion neurons, which communicate through 
electro-chemical signals. The neurons are connected through junctions called synapses. 
Each neuron receives thousands of connections with other neurons, constantly receiving 
incoming signals to reach the cell body. If the resulting sum of the signals surpasses a 
certain threshold, a response is sent through the axon [26]. The ANN attempts to recreate 
the computational mirror of the biological neural network, although it is not comparable 
since the number and complexity of neurons which used in a biological neural network is 
many times more than those in an artificial neutral network. 
 
 10 
 
ANN is composed of a large number of highly interconnected processing elements called 
artificial neurons (also known as "nodes"), classified into three layers of neurons, input 
nodes, hidden nodes, and output nodes as seen in (Fiqure1-1). The neurons work in unison 
to solve  complicated non-linear problems of multivariate systems [27]. Where the input 
nodes take in information, in the form which can be numerically expressed. 
 The information is presented as activation values, where each node is given a number, the 
higher the number, the greater the activation. This information is then passed throughout 
the network. Based on the connection strengths (weights), inhibition or excitation, and 
transfer functions, the activation value is passed from node to node. Each of the nodes 
sums the activation values it receives; it then modifies the value based on its transfer 
function. The activation flows through the network, through hidden layers, until it reaches 
the output nodes. The output nodes then reflect the input in a meaningful way to the 
outside world [28]. 
 As a result of its component the ANN has a remarkable ability to derive meaning from 
complicated or imprecise data, and can be used to extract patterns and detect trends that are 
too complex to be noticed by either humans or other computer techniques. 
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Figure (1-1): The Artificial Neural Network 
Neural network simulations appear to be a recent development. However, this field was 
established before the advent of computers, where the first neuron was produced in 1943 
by the neurophysiologist Warren McCulloch and the logician Walter Pits. Accordingly a 
wide variety of ANNs are developed and used to model real neural networks, and study 
behavior and control in animals and machines, but also there are ANNs which are used for 
engineering purposes, such as pattern recognition, forecasting, and data compression. 
Neural networks take a different approach to problem solving than that of conventional 
computers. Conventional computers use an algorithmic approach i.e. the computer follows 
a set of instructions in order to solve a problem. Unless the specific steps that the computer 
needs to follow are known the computer cannot solve the problem. That restricts the 
problem solving capability of conventional computers to problems that we already 
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understand and know how to solve. But computers would be so much more useful if they 
could do things that we don't exactly know how to do. However ANN offer a number of 
advantages, including requiring less formal statistical training, ability to implicitly detect 
complex nonlinear relationships between dependent and independent variables, ability to 
detect all possible interactions between predictor variables, and the availability of multiple 
training algorithms. Plus all these advantages the ANN is easy to use and understand 
compared to statistical methods. It is non-parametric model while most of statistical 
methods are parametric model that need higher background of statistic [29]. 
In the other hand, because the ANN finds out how to solve the problem by itself, its 
operation can be unpredictable. 
 
1.3.3 Model validation 
 
Quantitative Structure Activity Relationship (QSAR) is based on the hypothesis that 
changes in molecular structure reflect changes in the observed response or biological 
activity. The success of any quantitative structure–activity relationship model depends on 
the accuracy of the input data, selection of appropriate descriptors, statistical tools and the 
validation of the developed model. Validation is a crucial aspect of QSAR modeling. 
Validation is the process by which the reliability and significance of a procedure are 
established for a specific purpose [30]. 
 
QSAR model validation performed either by using the data that created the model (an 
internal validation) or by using a separate data set (an external validation). The internal 
validation are: least squares fit (R2), cross-validation (Q2) [31, 32], adjusted R2 (R2 adj), 
chi-squared test (2), root mean-squared error (RMSE), bootstrapping and scrambling (Y-
Randomization) [33, 34]. 
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The external method is performed by comparing the predicted and observed activities of an 
(sufficiently large) external test set of compounds that were not used in the model 
development. 
In current research, two internal validation methods have been used; cross-validation and 
scrambling (Y-Randomization). 
 
Cross-validation 
 
Cross-validation (CV, Q
2
, q
2
, or jack-knifing) is a common method for internal validation 
of a QSAR model. CV process repeats the regression many times on subsets of data. 
Usually each molecule is left out once (leave one out, LOO), in turn. Sometimes more than 
one molecule (leave many out, LMO) is left out at a time.  
 
Most of validation processes implement the leave one out (LOO) and leave many out 
(LMO) cross-validation procedures. The most common outcome parameters resulted from 
cross-validation procedures are cross-validated determination coefficient q
2
 (R
2
cv) and 
root mean squares error (RMSE), Figure 1-2. High R
2
cv and low RMSE values is a result 
of good and more predictive model and that lead to better description of the observed data. 
As well as the difference between coefficient of determination (R2) and Q2 value should 
not exceed 0.3 for good predictability. 
n
XX
RMSE
n
i
idelmoiobs   1
2
,, )(
 
Figure 1-2: Root Mean Squares Error (RMSE) equation. Where, Xobs is the observed values, 
Xmodel is the mean of the experimental bioactivities, and n is the number of 
molecules in the set of data being examined. 
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The cross-validation outcome R
2
 (Q
2
) equation as seen in (Figure 1-3), which is frequently 
used as a criterion of both robustness and predictive ability of the model. Many authors 
consider high Q
2
 (for instance, Q
2
 > 0.5) as an indicator or even as the ultimate proof of the 
high predictive power of the QSAR model. Therefore if the model have high predictive 
ability, then there is no need to test the models for their ability to predict the activity of 
compounds of an external test set [30]. 
 
 
 
 
 
      Figure 1-3: Cross-validation equation. Where PRESS is the predictive residual sum of 
the squares, yi is the experimental bioactivity for an individual compound 
in the training set, and ym is the mean of the experimental bioactivities 
 
Randomization test (Scrambling model)  
Randomization test (Scrambling model) is the second internal validation test performed in 
this research, which helps to ensure that the model is not due to a chance.  
The test performed by randomization of the dependent variables, in which the set of 
activity values is reassigned randomly to different molecules, and repeating the entire 
modeling procedure. This process is repeated many times. If the random models activity 
prediction is comparable to the original equation, then the predictive power of the model is 
poor and the observations are not sufficient to support the model [30]. 
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1.4 Software used in QSAR process 
 
There are many software available for QSAR development. These include specialized 
software for drawing chemical structures, interconverting chemical file formats, generating 
3D structures, calculating chemical descriptors, developing QSAR models, and general-
purpose software that have all the necessary components for QSAR development [35]. 
 
In the current research four softwares used; HyperChem (version 8.3 HyperChem, Inc.), 
Dragon software (version 2.1, Todeschini, R., Milano Chemometrics and QSAR Group. 
Different statistical packages such as: SPSS software (version 20, SPSS Inc.), MATLAB 
(version 6.50, Mathworks Inc.). 
 
 
1.4.1 HyperChem 
 
HyperChem is a sophisticated molecular modeling environment that is flexible, ease of use 
with high quality (Figure 1-4). As it combines 3D visualization and animation with 
quantum chemical calculations, molecular mechanics, and dynamics, HyperChem used to 
draw simple and complex molecular structures, structure optimization, calculate some 
QSAR properties, and use its output file as input file to another program called "Dragon" 
to calculate more structure related descriptors. In this research we drew the compounds 
structures and optimize each one then calculate certain properties. 
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Figure 1-4: HyperChem display screen 
1.4.2 Dragon 
 
DRAGON was developed in 1994 by Milano Chemometrics and QSAR Research 
Group with the name "WHIM/3D QSAR", being specific for the calculation of the WHIM 
descriptors [36]. Successively, a lot of other descriptors have been implemented leading to 
a new software, which in 1997 provided about 600 descriptors and was released with the 
name DRAGON [37]. 
DRAGON is user-friendly and easy to use software, and able to provide thousands of 
molecular descriptors that are divided into 18 logical blocks (Table 1-1). 
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                      Table 1-1: DRAGON descriptors blocks. 
 
 
 
 
 
 
 
 
 
 
 
 
     
1.4.3 SPSS 
SPSS, standing for Statistical Package for the Social Sciences, it is a powerful, user-
friendly. SPSS is a software package for the manipulation and statistical analysis of data, 
(Figure 1-5). It was developed in 1968 by three young men from disparate professional 
backgrounds Norman H. Nie, C. Hadlai (Tex) Hull and Dale H. Bent [38]. The idea was 
based on using statistics to turn raw data into information essential to decision-making 
SPSS for Windows offers a spreadsheet facility for entering and browsing the working data 
file — the Data Editor. Output from statistical procedures is displayed in a separate 
window — the Output Viewer. It takes the form of tables and graphics that can be 
manipulated interactively and can be copied directly into other applications [39]. 
ID Block description 
1 Constitutional descriptors 
         2 Topological descriptors 
3 Molecular walk counts 
4 BCUT descriptors 
5 Galvez topological charge indices 
6 2D autocorrelations 
7 Charge descriptors 
8 Aromaticity indices 
9 Randic molecular profiles 
10 Geometrical descriptors 
11 RDF descriptors 
12 3D-MoRSE descriptors 
13 WHIM descriptors 
14 GETAWAY descriptors 
15 Functional group counts 
16 Atom-centred fragments 
17 Empirical descriptors 
18 Properties 
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SPSS is very common and widely used by social science researchers. Also it is used by 
market researchers, health researchers, survey companies, government, education 
researchers, and others. In this research the SPSS will be used to perform MLR analysis. 
 
 
 
 
 
 
 
Figure 1-5: SPSS display screen 
 
1.4.4 MATLAB 
 
MATLAB stands for MATrix LABoratory and the software is built up around vectors and 
matrices. This makes the software particularly useful for linear algebra but MATLAB is 
also a great tool for solving algebraic and differential equations and for numerical 
integration. MATLAB has powerful graphic tools and can produce nice pictures in both 2D 
and 3D. It is also a programming language, and is one of the easiest programming 
languages for writing mathematical programs [40].  
The MATLAB mainly used in the current study to perform the cross validation, PCA and 
ANN. 
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1.5 Translocator protein (TSPO) preview:  
 
Translocator protein (TSPO), was known as the peripheral benzodiazepine receptor (PBR). 
First identified in 1977 based on its distinct pharmacology with high affinity binding to 
benzodiazepines in peripheral tissues [41-44]. The term ―peripheral‖ was used to 
distinguish it from the plasma membrane ―central‖ benzodiazepine receptor, a complex 
together with the γ-aminobutyric acid type A receptor that is important for inhibitory 
neurotransmission in the central nervous system [45, 46]. However it became clear that its 
density in the brain regions can equal or exceed the density of central benzodiazepine 
receptor (CBR) in the corresponding regions [47].  
 
TSPO is a protein of 18 kDa consisting of 169 amino acids [48], a five a -helices 
composed of 21 hydrophobic residues. The N-terminus of the sequence is located in the 
mitochondrial domain, while the C-terminus is exposed to the cytoplasm. The 
transmembrane regions are connected by loops rich in hydrophilic residues [49]. TSPO is 
strictly associated in a trimeric complex with the 32 kDa voltage dependent anion channel 
(VDAC), and 30 kDa adenine nucleotide translocase (ANT), thus forming the 
mitochondrial permeability transition pore (MPTP). 
TSPO amino acid sequence shows conservation throughout evolution. TSPO in the 
photosynthetic bacteria Rhodobacter sphaeroides shows a 33.5% identity to human TSPO. 
Both human and mouse TSPO genes translate to a 169-amino acid protein with 81% 
sequence homology [50, 51]. Relatively the protein sequence of TSPO is conserved from 
bacteria to humans.  
Expression of TSPO has been reported in different tissues including heart, brain, lung, 
spleen, testis, ovary, adrenal, kidney, bone marrow, salivary gland, adipose tissue, skin, 
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and liver [52-54]; and within these tissues, TSPO expression is regional and/or cell type 
specific. Also TSPO is expressed at low levels in other subcellular compartments such as 
plasma membranes and the nuclear fraction of cells [55].  
TSPO binding sites 
 Although research suggests that there exist multiple TSPO binding sites, the nature of 
these sites and their functional significance is poorly understood. Two ligands have been 
essential for characterizing the TSPO: the benzodiazepine Ro 5-4864 and the isoquinoline 
carboxamide PK11195, both of which are selective for the TSPO and display nanomolar 
binding affinity. Although these ligands exhibit saturable binding and reciprocal 
competition in radio ligand binding assays [56]. Furthermore, site-directed mutagenesis 
studies suggest certain residues in the first putative loop of TSPO are important for the 
binding of Ro 5-4864 but not PK11195. Thus, it is thought that PK11195 and Ro 5- 4864 
bind to heterogeneous sites at TSPO, either overlapping or allosterically coupled. Studies 
also describe PK11195 binding to multiple sites, which contradicts the initial finding that it 
bound to a single population of saturable sites. Scatchard analysis of 3HPK11195 binding 
to Ehrlich tumor cells revealed 2 independent binding sites [57]. 
TSPO Pharmacology 
Benzodiazepine Ro5-4864 [4′-chlorodiazepam; 7-Chloro-5-(4-chlorophenyl)-1,3-dihydro-
1-methyl-2H-1,4-benzodiazepin-2-one] and a nonbenzodiazepine PK11195 [an 
isoquinoline carboxamide derivative, 1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-
isoquinolinecarboxamide] were initially established as prototypical TSPO-binding 
chemicals, because they bind to TSPO but not to γ-aminobutyric acid type A receptor [58, 
59]. Based on thermodynamic studies [60], and their opposing effects on neuronal seizures 
[61], PK11195 was classified as an antagonist and Ro5-4864 as an agonist. This 
pharmacology has been extensively used in attempts to elucidate the physiological 
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relevance of TSPO [62]. Although these studies did not readily reveal TSPO function, the 
ability of these chemicals in detecting TSPO with reasonable accuracy, and the 
pathological TSPO up-regulation seen at sites of inflammation led to the development of 
TSPO as a diagnostic target [63]. Radiolabeled forms of these chemicals that bind TSPO 
could be used to detect inflammatory lesions in vivo in a variety of human diseases using 
positron emission tomography [64, 65]. Clinical trials for different TSPO-binding agents 
focused on the diagnosis of various pathologies including traumatic brain injury, 
Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, encephalopathy, autism, 
neuroinflammation, neurodegeneration, dementia, and neurocysticercosis. 
 Human clinical trials to detect cardiac sarcoidosis (NCT02017522), carotid atherosclerosis 
(NCT00547976), and squamous and basal cell carcinomas (NCT01265472). Thus, remain 
an area of active research.  
TSPO is said to be involved in a variety of biological processes including cholesterol 
transport, steroidogenesis, calcium homeostasis, lipid metabolism, mitochondrial 
oxidation, cell growth and differentiation, apoptosis induction, and regulation of immune 
functions [55].  
 
 
TSPO in Brain and neurodegenerative diseases  
Brain expression of TSPO in physiological conditions is low. In the CNS, TSPO is mainly 
found in glia and at very low levels in neurons [63, 66, 67]. However TSPO ligands are 
used for brain imaging of neuroinflammation, since TSPO is upregulated at sites of injury 
and inflammation, as well as in several neuropathological conditions including stroke and 
neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease, 
Huntington’s disease, Multiple sclerosis and Amyotrophic lateral sclerosis [68-71]. Under 
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these conditions, the expression of TSPO is highly enhanced in reactive microglia and 
astrocytes [72-75]. 
TSPO is also upregulated in microglia and astrocytes in response to lesions, and its level of 
upregulation is directly related to the degree of damage. Therefore several studies suggest 
that TSPO ligands could be used as markers for the state and progression of Traumatic 
brain injury (TBI). In addition, some studies have addressed the neuroprotective effects of 
TSPO ligands in experimental models of brain injury [63, 76]. 
Other several studies have associated psychiatric disorders with a down regulation of 
TSPO expression in peripheral cells. Decreased TSPO expression has been found in the 
platelets and lymphocytes of patients with anxiety disorders [77-79], in the platelets of 
patients suffering from schizophrenia [80] and post-traumatic stress disorder [81] and in a 
suicidal adolescent population [82]. However, increased TSPO density, measured by 
distribution volume by positron emission tomography, has been detected in the prefrontal 
cortex, the anterior cingulate cortex and insula of patients with a major depressive episode 
[83]. In these patients, greater TSPO density in the anterior cingulate cortex correlated with 
greater depression severity [83]. 
 
Thus TSPO can be exploited as a diagnostic marker to follow disease Progression and 
therapy efficacy by means of the biomedical imaging technique PET (positron emission 
tomography) but also as a therapeutic target [84]. Although imaging complications have 
been encountered as a result of in vivo metabolism of these TSPO-binding PET tracers and 
aberrant signals contributing to nonspecific noise in some cases, new synthetic TSPO-
binding chemicals are being developed to tackle these drawbacks [75]. Therefore, 
diagnostic imaging is probably the primary clinical value that TSPO research has to offer 
at the present time [85]. 
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1.6 Research objective 
 
The main objective of this study is to develop QSAR models for the activity of 136 
chemical compounds of Translocator protein (TSPO) by applying different statistical 
qualities; MLR and PC-ANN. The resulted models will be used for designing and 
prediction of the activity of new ligands.   
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2. QSAR process method: 
 
Quantitative structure-activity relationship (QSAR), is an analytical application that is used 
to interpret the quantitative relationship between the biological activities and particular 
molecules structures. And to do that the molecular structure and their activity against 
certain target should be known and experimentally estimated. 
As previously mentioned in Chapter 1; QSAR model development process is typically 
performed in successive steps divided into three steps; Data preparation, data analysis, and 
model validation. 
2.1 Data preparation 
2.1.1    Dataset 
 
136 compounds and their related observed activity (pIC50) against Translocator protein 
(TSPO) are carefully taken from references [49, 86-89], which shared the same method of 
determination of ligands-Receptor activities using rat cortex membrane. The 136 
compounds are divided into 18 chemical structure cores as shown in table 2-1. 
                    Table 2-1: Dataset, Compounds have activity against TSPO 
 
 26 
 
*: Reference [86] 
 
  
 
 
 
Compounds 
Number 
Index 
* 
X Y R1 R2 R3 pIC50 
001 3a H CH CH2C6H5 H H 5.569 
002 3b H CH CH2C6H5 CH3 H 7.194 
003 3c H N CH2C6H5 H H 7.194 
004 3d H N CH2C6H5 CH3 H 7.420 
005 3e H CH CH2C6H5 H CH3 5.180 
006 3f H CH CH2C6H5 CH3 CH3 8.009 
007 3g H N CH2C6H5 H CH3 4.988 
008 3h H N CH2C6H5 CH3 CH3 8.337 
009 3i F N CH2C6H5 H CH3 5.827 
010 3j F N CH2C6H5 CH3 CH3 8.658 
011 3k H N CH2C6H5 CH2C6H5 CH3 7.959 
012 3l H N CH2C6H5 CH3 CH2OH 8.060 
013 3m H N CH2C6H5 CH3 CH2CL 9.347 
014 3n H N CH2C6H5 CH3 CH2N(C2H5)
2 
7.921 
015 3o H N CH2C6H5 CH3 CH2N(C2H5)
CH2C6H5 
7.886 
016 3p H N CH2CCH CH3 CH3 7.495 
 27 
 
Compounds 
Number 
Index * X Y Z R1 R2 R3 pIC50 
017 1 H H Cl n-C4H9 n-C4H9 H 8.230 
018 2 H Cl Cl n-C4H9 n-C4H9 H 8.104 
019 3 Cl Cl Cl n-C4H9 n-C4H9 H 8.284 
020 4 Cl Cl Cl n-C6H13 n-C6H13 H 6.424 
021 5 Cl H Cl n-C4H9 n-C4H9 H 8.485 
022 6 Cl H Cl n-C6H13 n-C6H13 H 8.292 
023 7 Cl H H n-C4H9 C6H5 H 7.939 
024 8 Cl CL Cl n-C4H9 C6H5 H 7.876 
025 9 Cl H Cl n-C4H9 C6H5 H 8.824 
026 10 Cl CL H n-C4H9 CH2C6H6 H 7.616 
027 11 Cl CL Cl tert-C4H9 CH2C6H6 H 5.464 
028 12 Cl CL Cl n-C3H7 4-NO2-CH2C6H5 H 7.566 
029 13 Cl CL Cl C6H5 H H 7.701 
030 14 Cl CL Cl CH2CHCH2 CH2CHCH2 H 8.092 
031 15 Cl CL Cl -(CH2)4- H 6.668 
032 16 Cl CL H -(CH2)4- H 5.907 
033 17 Cl Cl H -(CH2)5- H 6.804 
034 18 Cl Cl Cl -(CH2)5- H 8.301 
035 19 Cl H Cl -CH2CH(COOC2H5)(CH2)3- H 7.454 
036 20 Cl Cl Cl -CH2CH(COOC2H5)(CH2)3- H 6.845 
037 21 Cl Cl Cl -(CH2)2N(CH2C6H5)(CH2)2- H 4.682 
038 22 Cl Cl H - - - 7.412 
039 23 Cl Cl Cl - - - 8.313 
040 24 Cl CL H 2-
pyridylethyl 
CH3 H 5.663 
  041 25 Cl Cl Cl 2-
pyridylethyl 
CH3 H 6.046 
042 26 Cl CL H 2-pyridyl H H 5.677 
043 27 Cl CL CL n-C4H9 H H 6.409 
044 28 Cl Cl Cl C6H11 H H 6.640 
045 29 Cl Cl H C6H11 H H 5.878 
046 30 Cl Cl Cl CH2C6H5 H H 6.772 
047 31 Cl Cl Cl n-C3H7 n-C3H7 CH3 5.920 
048 32 Cl Cl Cl C6H11 CH3 CH3 5.288 
049 33 Cl Cl Cl CH2C6H5 CH3 CH3 5.005 
050 34 Cl Cl Cl n-C4H9 CH3 H 9.347 
051 35 Cl Cl H n-C4H9 CH3 H 8.456 
052 36 Cl Cl Cl C6H5 CH3 H 9.481 
053 37 Cl Cl Cl CH2C6H5 CH3 H 8.623 
                   *: Reference [87]. 
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Compounds 
Number 
Index * R1 R2 X pIC50 
054 10a CH3 (CH2)3CH3 H 7.187 
055 10b C2H5 C2H5 H 6.745 
056 10c CH(CH3)2 CH(CH3)2 H 5.856 
057 10d (CH2)2CH3 (CH2)2CH3 H 7.046 
058 10e (CH2)3CH3 (CH2)3CH3 H 6.818 
059 10f CH3 C6H5 H 6.932 
060 10g CH3 p-Cl-C6H4 H 8.745 
061 10h CH3 p-CH3OC6H4 H 7.769 
062 10i CH3 CH2C6H5 H 6.055 
063 10j CH2C6H5 C2H5 H 6.658 
064 10k CH2C6H5 CH(CH3)2 H 6.517 
065 10l CH2C6H5 (CH2)3CH3 H 6.157 
066 10m CH2C6H5 CH2C6H5 H 5.460 
067 10n CH3 (CH2)3CH3 F 6.959 
068 10o C2H5 C2H5 F 5.644 
069 10p (CH2)2CH3 (CH2)2CH3 F 7.060 
070 10q CH3 p-Cl-C6H4 F 8.167 
071 10r CH3 (CH2)3CH3 Cl 6.842 
072 10s (CH2)2CH3 (CH2)2CH3 Cl 7.046 
073 10t CH3 p-Cl-C6H4 Cl 7.796 
074 11a CH3 (CH2)3CH3 H 9.854 
075 11b C2H5 C2H5 H 9.081 
076 11e (CH2)3CH3 (CH2)3CH3 H 9.469 
077 11g CH3 p-Cl-C6H4 H 9.886 
078 11n CH3 (CH2)3CH3 F 9.886 
079 11q CH3 p-Cl-C6H4 F 9.553 
         *: Reference [88]. 
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          *: Reference [89]. 
 
Compounds 
Number 
Index * R1 R2 R3 X pIC50 
080 8a 4-(CH3O)C6H4 CH3 Cl =O 9.046 
081 8b 4-ClC6H4 CH3 Cl =O 9.208 
082 8c CH2C6H5 CH3 Cl =O 7.585 
083 8d CH2C6H5 C2H5 Cl =O 7.824 
084 8e (CH2)5CH3 (CH2)5CH3 Cl =O 7.678 
085 9a C6H5 CH3 Cl =O 7.357 
086 9b 4-(CH3O)C6H4 H Cl =O 7.119 
087 9c 4-(OH) C6H4 CH3 Cl =O 7.131 
088 9d CH2CCH CH3 Cl =O 6.495 
089 9e 4-(CH3O)C6H4 CH3 H =O 7.921 
090 9f 4-ClC6H4 CH3 H =O 8 
091 9g 4-(CH3O)C6H4 CH3 Cl =H2 5.627 
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Compounds Number Index * Bridge (B) X R1 R2 pIC50 
092 7a n-Bu-CH - Benzyl - 6.092 
093 7b CH2-CH2-CH2 - s-Bu - 5.921 
094 7c CH2-CH2-CH2 - Benzyl - 6.777 
095 8a - H s-Bu H 6.638 
096 8b - F s-Bu H 7.886 
097 8c - H Benzyl H 5.921 
098 8d - H 4-Cl- 
Benzyl 
H 5.769 
099 8e - F 4-Cl- 
Benzyl 
H 6.569 
100 8f - H s-Bu Me 8.678 
101 8g - F s-Bu Me 8.538 
102 8h - H Benzyl Me 8.678 
103 8i - H 4-Cl- 
Benzyl 
Me 8.009 
104 8j - F 4-Cl- 
Benzyl 
Me 8.469 
105 8k - H 4-Cl-Ph Me 8.194 
106 8l - H 4-MeO-Ph Me 8.056 
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*: Reference [49] 
 
 
Compounds 
Number 
Index * X R pIC50 
117 4a CH - 8.301 
118 4b N - 7.569 
119 5a - Me 6.387 
120 5b - CL 6.678 
*: Reference [49] 
107 9a CH2 - s-Bu - 6.208 
108 9b CH2 - Benzyl - 6.319 
109 9c CH2-CH2-CH2 - s-Bu - 6.108 
110 9d CH=CH-CH2 - s-Bu - 6.309 
111 9e CH=CH-CH2 - Benzyl - 7.347 
112 10a - - s-Bu H 6.259 
113 10b - - s-Bu Me 7.959 
114 10c - - Benzyl Me 8.509 
115 11a CH2-CH2 - - - 8.051 
116 11b O-CH2-CH2 - - - 8 
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O
N
R2
R1
N
133-134 N
O
N
N
135
 
Compounds 
Number 
Index * R R1 R2 pIC50 
121 6a CH2N(Et)Bn - - 6.155 
122 6b N(Et)Bn - - 6.268 
123 12a Cl - - 5.432 
124 12b CH2THIQ - - 5.926 
125 13a CONMe2 - - 6.640 
126 13b CONEt2 - - 6.428 
127 13c CON(n-Pr)2 - - 6.341 
128 13d CON(Me)Ph - - 5.880 
129 13e CON(Me)4-Cl-Ph - - 5.606 
130 13f CON(H)n-Pr - - 6.059 
131 13g CON(H)Bn - - 5.538 
132 13h H - - 5.469 
133 15b - Et Et 5.086 
134 15c - n-Pr n-Pr 5.052 
135 16 - - - 8.387 
         *: Reference [49] 
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Comp. 
Number 
Reference  
Compound  
pIC50 
[86] 
 
pIC50 
[87] 
pIC50 
[88] 
pIC50 
 [89] 
pIC50 
 [49] 
136 PK11195 8.075 8.155 8.886 8.677 8.657 
 
2.1.2 Compounds optimization 
 
To calculate the properties of each molecule; a well-defined structure which represents a 
minimum potential energy surface is needed. Therefore after choosing the 136 compounds, 
start drawing each compound structure using HyperChem to optimize it. 
 Steps of optimization using HyperChem: 
1. Draw the compound structure on HyperChem Workspace using drawing tools, as 
seen in figure 2-1. 
2. The drawn compound is in two- dimensional (2D) form, therefore a conversion from 
the 2D compound structure into a 3D structure using the HyperChem Model Builder 
is needed. So select (Add H and Model build) from the Build menu to convert the 2D 
form to 3D. 
3. Click start log on the File menu to save the new drawn structure, name the file, and 
choose a directory to save in it,  
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4. Then in order to perform the optimization of the compound structure; choose the 
semi-empirical calculation from the setup tab, accordingly a dialog box of types of 
semi-empirical methods will open. Thus choose from it the AM1 method and after 
that press on the options button to determine the geometry optimization parameters; 
total charge = 0, spin multiplicity = 1, spin pairing = RHF (Restricted Hartree-Fock), 
convergence limit = 0.1.                                                                                      
         These parameters mean that the calculation ends when the difference in energy after 
two consecutive iterations is less than 0.1 kcal/mol. The calculation is performed on 
the lowest state without special convergence acceleration. 
5. Click OK to close the semi-empirical options dialog box, and then click OK to close 
the semi-empirical method dialog box. 
6. To start the optimization process, click on geometry optimization from HyperChem 
menu. A dialog box of Semi-empirical optimization will open. Set Polak-Ribiere as 
algorithm method, 0.1 for RMS gradient and keep the defaulted value for the rest of 
the fields. 
          Then click OK so the optimization process initiate. 
7. When the optimization process stopped, select stop log from the file menu to save the 
calculation output as log file. The output file will be saved in (.hin) format. 
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     Figure 2-1: Drawing using HyperChem 
 
2.1.3 Descriptors calculation 
 
To establish QSAR we are not able mathematically to link between the chemical structures 
and their activity directly, thus a numerical factor is needed to link between the chemical 
structure and the activity. This numerical factor is the chemical structure properties which 
called Molecular Descriptors 
“The molecular descriptor is the final result of a logic and mathematical procedure which 
transforms chemical information encoded within a symbolic representation of a molecule 
 36 
 
into a useful number or the result of some standardized experiment [90] .‖ Molecular 
descriptors play a fundamental role in chemistry, pharmaceutical sciences, environmental 
protection policy, health research and quality control. It has been used to predict biological 
and physicochemical properties of molecules (QSAR/QSPR) and for virtual screening of 
molecule libraries. 
There are simple molecular descriptors derived by counting some atom-types or structural 
fragments in the molecule, other derived from algorithms applied to a topological 
representation (molecular graph) and usually called topological or 2D-descriptors, and 
there are molecular descriptors derived from a geometrical representation called 
geometrical or 3D-descriptors. 
In current research we have been using two software's to calculate different descriptors; 
HyperChem and Dragon. 
2.1.3.1 Descriptors calculated by HyperChem 
 
a. Descriptors extracted from the output log file 
The HyperChem calculate the quantum chemical descriptors and more. We open the output 
log file for each optimized chemical structure and take from it the following values then 
put the values in excel file: 
 HOMO (highest occupied molecular orbital). 
 LUMO (Lowest occupied molecular orbital). 
 Heat of formation (kcal/mol). 
 Dipole moment (Debyes). 
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From the HOMO and LUMO values we can calculate the below descriptors: 
 Hardness (0.5* (LUMO - HOMO)). 
 Softness (1/Hardness). 
 Electronegativity (-0.5* (LUMO + HOMO)). 
 Electrophilicity    (Electronegativity* Electronegativity/(2*Hardness)) [91]. 
 
b. Descriptors calculated from the HyperChem using the optimized structures 
We can calculate certain descriptors by performing the following steps: 
1. Open the HyperChem file of the optimized 3D structure of each compound in the 
dataset. 
2. Then choose QSAR properties from the computer tab, thus a dialog box contain the 
below properties will open (Fig 2-2). 
 Surface Area (Approx). 
 Surface Area (Grid). 
 Volume. 
 Hydration Energy. 
 Log P. 
 Refractivity. 
 Polarizability. 
 Mass. 
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Figure 2-2: QSAR Properties dialog box in HyperChem software. 
3. Choose one of the properties in the dialog box and press on Compute button, then 
copy the result to an excel file. Repeat this step to calculate all the properties one by 
one for each chemical structure. 
2.1.3.2 Descriptors calculated by Dragon 
 
DRAGON 2.1 software provides the calculation of thousands of descriptors which are 
divided into 18 blocks (groups) of descriptors as seen in table 1- 1, also some of the 
descriptor groups is mentioned in table 2-2.  
2.1.3.2.1 Brief description about Dragon descriptors: 
 
Constitutional descriptors are the most simple and commonly used descriptors, reflecting 
the composition of a molecule without any geometrical information. Examples of these 
descriptors are the number of atoms, bonds, rings, specific atom types, rotatable bonds, etc.  
The descriptor blocks: topological, walk and path counts, information indices, 2D 
autocorrelation, and charge indices contain topological and topographic descriptors. 
Topological descriptors are based on a graph representation of the molecule. They are 
numerical quantifiers of molecular topology obtained by the application of algebraic 
operators to matrices representing molecular graphs. They can be sensitive to one or more 
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structural features of the molecule such as size, shape, symmetry, branching and cyclicity 
and can also encode chemical information concerning atom type and bond multiplicity. 
Topographic indices are derived from the graph representation of molecules in the same 
way as the topological indices, but using the geometric distances between atoms instead of 
the topological distances. 
 The blocks: geometrical, RDF, 3D-MoRSE, WHIM, and GETAWAY descriptors include 
descriptors derived from the knowledge of the 3D structure of the molecule. Some of the 
Molecular properties block derived from literature models, such as Moriguchi logP, 
Ghose-Crippen logP, Lipinski rule-of-five, etc. 
However the descriptors groups are divided into four types: 
0D: Constitutional descriptors.  
1D:  Empirical, Functional groups, Properties, Atom-centred fragments descriptors. 
2D: Autocorrelations, Topological, Molecular walk counts, Galvez topological charge     
indices, BCUT descriptors.  
3D: Geometrical, Randic molecular profiles, WHIM, GETAWAY, RDF, 3D-MoRSE, 
Charge descriptors. 
 
2.1.3.2.2 Steps to perform descriptors calculation using DRAGON software: 
 
1. After starting DRAGON, press on calculate descriptors button from the left side list 
of program interface. A dialog box will open, to select the files for calculations. 
2. Select the output files resulted from the HyperChem structures optimization process 
and choose the type of the file to be in (.hin) format then choose the type of 
descriptor group to be calculated, then press run. 
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3. Save the output file in notepad format once the calculation of input compound file 
for certain group of descriptors is done.  
4. Change the format file from the notepad to excel format. So we can use it as input 
file for SPSS and other analysis softwares. 
5. Accordingly repeat these steps for all compounds each time calculate one group of 
descriptors, till all descriptors groups for each compound is calculated. 
 
      Table 2-2: Brief description of some of the descriptors used in this study 
Descriptors Descriptors Group 
Molecular weight (MW),  number of atoms (nAT),  number of non H-
atoms (nSK), number of bonds (nBT), number of multiple bonds (nBM), 
number of rings (nCIC), number of circuits (nCIR), number of H-bond 
donor (nHDon), number of H-bond acceptor (nHAcc). 
 
Constitutional 
Information index molecular size (ISIZ), connectivity indices(X), average 
connectivity index (XA), kier symmetry index (S0K), total walk count 
(TWC), Zagreb index (Z), Schultz molecular topological index, Balaban j 
index (J), Wiener w index (W) 
 
Topological indices 
Highest occupied molecular orbital energy(EHOMO), Lowest unoccupied 
molecular orbital energy (ELUMO), Most positive charges(MPC), Least 
negative charges (LNC), Most negative charges(MNC),  Sum of positive 
charges(SPC), Sum of negative charges (SNC),  Sum of squares of 
positive charges (SSPC),  Sum of squares of negative 
charges(SSNC),Sum of squares of charges (SSC), Sum of absolute of 
charges (SAC) ,molecular Dipole moment (DM) , Electronegativity (χ=-
0.5(EHOMO-ELUMO)).Hardness(η=0.5(EHOMO+ELUMO)).Softness 
(S=1\η).Electrophilicity (ω=χ2/2η). Heat of formation (Hf). 
Quantum 
Chemical 
Octanol-water partition coefficient (LogP), hydration energy (HE) 
polarizability (Pol), refractivity (Ref), volume (V), surface area (SA), 
Chemical 
descriptors 
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2.2 Data analysis 
 
2.2.1 Multiple linear regression (MLR) 
 
MLR simultaneously considers the relationship between dependent variables (biological 
activity) and a independent variable (theoretical molecular descriptors) by fitting a linear 
equation to observed data using SPSS software. The MLR is the first statistical step that 
done because of the assumption that there is a linear correlation between the independent 
variables (descriptors) and the response variable (Y, Activity in our study). 
2.2.1.1 Steps to perform MLR for each descriptor group using SPSS: 
 
1. Import to SPSS one of the output files which resulted from the descriptors 
calculation on HyperChem and DRAGON (e.g. Constitutional descriptors file for all 
the compounds). The file will contain the activities of all compounds and each 
compound related calculated descriptors as seen in table 2-3. 
 
  Table 2-3: The format of the input file in SPSS to perform MLR (The activities of all 
compounds and their corresponding properties.  
Activity 
(IC50) 
Molecular 
weight (MW) 
Sum of atomic van 
der Waals volumes 
(sv) 
Sum of atomic 
Sanderson 
electronegativities 
(Se) 
Sum of atomic 
polarizabilities 
(Sp) 
5.569 337.44 30.89 44.43 32.28 
7.194 351.47 32.48 47.32 34.04 
7.194 338.43 30.28 43.65 31.53 
7.420 352.46 31.88 46.54 33.29 
5.180 351.47 32.48 47.32 34.04 
8.009 365.5 34.08 50.2 35.8 
4.988 352.46 31.88 46.54 33.29 
8.337 366.49 33.48 49.42 35.04 
5.827 370.45 31.99 47.05 33.22 
8.658 384.48 33.59 49.94 34.98 
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2.  After importing the file data to the SPSS, press on Analyze tab, choose regression ► 
Linear as seen in figure 2-3. Thus a dialog box of linear regression as seen in figure 
2-4 will open to set the below fields: 
 First set IC50 as a dependent variable and the descriptors as independent variables. 
And also choose stepwise method for analysis method. 
 Then press on options button. Another dialog box will open to set the F value (F 
entry and F removal). Keep changing the F value till getting a convincing results. 
 And then press on Statistics to click on the field of Estimate Regression coefficient. 
 After that press on save button, and click on the unstandardized predicted values 
field. 
3. Click Ok button on the linear regression dialog box, in order to start the MLR. 
4. Repeat the previous steps on each descriptors group file. 
5. Choose the best model from each descriptor's group output. The best model which 
has higher R value and minimum number of descriptors among the results of each 
group. 
Figure 2-3: Choosing linear regression analysis using SPSS. 
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Figure 2-4: Dialog box which open after choosing the linear regression analysis. 
 
2.2.1.2 Steps to perform MLR for all the descriptors resulted from the first MLR   
using the SPSS: 
 
1. After choosing the best model for each descriptor's group, gather all the descriptors 
which mentioned in the best models in one file. 
2. Then import the prepared file into the SPSS and follow the steps of MLR as in 
section 2.2.1.1. 
3. From the resulted models; choose all the models having R2 ≥ 0.6 [92]. 
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2.2.2 MLR Model validation 
 
Model validation has been the subject of much recent debate in the scientific and 
regulatory communities. It was considered important to develop an internationally 
recognized set of principles for QSAR validation, to provide regulatory bodies with a 
scientific basis for making decisions on the acceptability of QSAR estimates of regulatory 
endpoints, and to promote the mutual acceptance of QSAR model. In current research, two 
internal validation methods have been performed to validate the MLR and the ANN 
resulted models; cross-validation and scrambling (Y-Randomization) respectively.  
2.2.2.1 Cross-validation 
 
The cross validation is used to validate the models resulted from the MLR. And it's divided 
into two types of procedures: leave one out (LOO) and leave many out (LMO) cross-
validation. 
2.2.2.1.1 Steps to perform leave one out (LOO) using MATLAB 
 
1. Prepare a file which contains in the first column the observed activity and then 
comes the predicted activities of each model resulted from the MLR with R
2
 ≥ 0.6. 
Where the predicted activities value taken from SPSS. 
2. By running a special MATLAB script to perform LOO and entering the file name, 
the MATLAB will ask for the model number and after that will ask to enter the 
number of descriptors for the model of interest. 
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3. A proper output file should look like:  
       Model   PRESS      SPRESS    SST        R2CV     PRESS/SST    PSE        RSEP 
     ------------------------------------------------------------------------------- 
1   25.0874    0.7155    16.9432    -0.4807    1.4807     0.6693     61.1801 
4. Choose the models which have PRESS/SST value < 0.4, and compare it with the 
LMO results, and continue with the chosen models to the PCA and ANN. 
2.2.2.1.2 Steps to perform leave many out (LMO) using MATLAB 
 
1. Prepare a file of each model alone containing the observed activity and the 
descriptors of the model.  
2. Run certain MATLAB script, and choose the data file. 
3. A proper output file should look like:  
PRESS      SPRESS     SST        R2CV     PRESS/SST    PSE        RSEP 
-------------------------------------------------------------------------------- 
45.7577  1.0198     42.6208     -0.0736     1.0736     0.9292     44.1042 
4. Repeat the previous steps for each prepared model file. 
5. Choose the models which have PRESS/SST value < 0.4, and compare it with the 
LOO results, and continue with the chosen models to the PCA and ANN. 
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2.2.3 Principal component analysis (PCA) 
 
Principal components analysis (PCA), It is a way of identifying patterns in data, and 
expressing the data in order to highlight their similarities and differences. Therefore the 
PCA is used to divide the dataset into three groups; training, validation and test set. As 
dividing the data should not be done randomly, instead, use the factor spaces of the 
descriptors and activity data. To do so, gather the descriptors and the activities in a single 
matrix (X). Perform principal component analysis (PCA) on X and then plot the first score 
against the second.  You will obtain a scatter distribution of data (molecules) in the two 
first factor spaces. Select the training set molecules from these data points so they span the 
same space of the entire data. Data division should be done as to have 60% of the data in 
the training set and 20% for each of the validation and test sets.  
 
Steps to perform PCA using MATLAB: 
1. Open MATLAB, and Run special MATLAB script to plot the first two PCs. 
2. Then the MATLAB will ask for the data excel file name. Thus enter the name of the 
file that contains the activities and all descriptors of models which were chosen after 
the second MLR validation. 
3. A figure of first two PCs will produced, from plotting (new data (:,x),new data 
(:,y),'+').  
        Where: x label ('xth Principal Component'); y label ('yth Principal Component'). 
4. Using the data distribution from the figure produced for the first two PCs, select the 
training, validation and test sets molecules.  
 
Hint: If the first two PCs were not enough to describe the data distribution, plotting the 
third PC can be helpful.  
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2.2.4 Artificial Neural Networks (ANN) 
 
Artificial Neural Networks (ANN) is used either when the linear method of analysis is not 
producing good predicting models or when more evidence that the linear method of 
analysis is good predicting method. 
2.2.4.1 Steps to perform ANN for each model using MATLAB: 
 
1. Use the same models which used in PCA to divide the dataset, prepare excel file of 
activity and descriptors for each model. 
2. Open MATLAB, and Run special MATLAB script for ANN. 
3. Then the MATLAB will ask for the data excel file name. Thus enter the name of the 
file. 
4. After that the MATLAB will ask for model number and the number of hidden nodes, 
see figure 2-5.  
5. Choose the best models which have high R value for test set and low PRESS and 
RESP values. 
 
 
 
 
 
 
Figure 2-5: MATLAB Command window asking for file name, model number and 
number of hidden nodes. 
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2.2.4.2 Steps to perform ANN of the best models with range of hidden nodes (Hn) using 
MATLAB: 
1. After choosing the optimal models based on the first ANN round, perform the ANN 
again for each model with range of hidden nodes starting from 5 to 20 by repeating 
the same steps in section 2.2.4.1.  
2. Pick best models having high R value for test set, low PRESS, low RESP values, and 
small number of hidden nodes. 
2.2.5 Randomization test (chance correlation or scrambling model)  
 
Randomization test is performed in this research to ensure that the ANN resulted model is 
not due to a chance.  
Steps to perform Randomization test using MATLAB: 
1. Prepare file for each model resulted from the ANN, the file content is similar to the 
content of the LMO data files.  
2. Run special MATLAB script, then enter the data file name and the number of trail 
when asked to. 
3. Repeat the test for each model more than ten times. 
Summary of QSAR process: 
 Dataset preparation (Chemical structure’s and their pIC50) 
 Geometry optimization through semi-empirical quantum mechanics using   
HyperChem. 
 Descriptors calculation using HyperChem and Dragon. 
 MLR Model building using SPSS as well as validation of these models  
 PC-ANN statistical model using MATLAB as well as validation of the models 
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3. Results and Discussion: 
 
QSAR models were developed as a result of this study using the 136 compounds and their 
related observed activity (pIC50) against Translocator protein (TSPO).  
3.2 Data preparation results 
 
 Compounds optimization using HyperChem resulted with optimized 136 compounds, 
through semi-empirical AM1 (Austin Model 1) method. Where the semi-empirical 
method is used because it is very fast compared with ab initio method, applicable to 
large molecules, and give accurate results. 
As well AM1 prove that it’s more reliable method than other semi-empirical methods 
(e.g. MNDO). 
  
 Descriptors calculation using HyperChem; allow to calculate one group of descriptors 
called G-16 quantum chemical descriptors. All the descriptors calculated through 
HyperChem is mentioned below and in section 2.1.3.1. 
 HOMO (highest occupied molecular orbital). 
 LUMO (Lowest occupied molecular orbital). 
 Heat of formation (kcal/mol). 
 Dipole moment (Debyes). 
 Log P. 
 Hardness (0.5* (LUMO - HOMO)). 
 Softness (1/Hardness). 
 Electronegativity (-0.5* (LUMO + HOMO)). 
 Electrophilicity    (Electronegativity* Electronegativity/(2*Hardness)) [91]. 
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 Surface Area (Approx). 
 Surface Area (Grid). 
 Volume. 
 Hydration Energy. 
 Refractivity. 
 Polarizability. 
 Mass. 
 Descriptors calculation using Dragon; 1235 descriptors have been calculated, in which 
represented through 18 groups. The results are explained below: 
 Two groups (Empirical and Properties descriptors) were constant or near 
constant.  Thus Dragon software discard these groups of descriptors because 
they are correlated with each other and with activity at the same time.  
 Other groups of descriptors; constitutional, topological, molecular walk counts, 
BCUT, Galvez topological charge indices, 2D autocorrelations, charge 
descriptors, aromaticity indices, Randic molecular profiles, geometrical, RDF, 
3D-MoRSe, WHIM, GETAWAY, functional, and atom-centered fragments 
were calculated with non-constant descriptors.  
Examples: A 37 descriptors were calculated within the constitutional group, a 
225 descriptors within the topological group and so on... 
 Performing the first MLR using SPSS, in which an MLR for each group of descriptors 
performed separately, except for the groups which contain small number of descriptors 
such as charge descriptors, aromaticity indices and G-16 quantum chemical were 
gathered in one input file for the MLR.   
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Results of first MLR is summarized in table 3-1, where (No.) refers to group number, 
(R) refers to correlation coefficient, (R
2
) refers to coefficient of determination, (R
2
adj.) 
refers to adjusted R
2 
, and selected descriptors refer to chosen descriptors by MLR 
model.  
 
Table 3-1: MLR Models resulted from each group of descriptors. 
No. Group name 
# of 
calculated 
descriptors 
R R
2
 R
2
adj. 
Standard 
Error of 
estimation 
Selected descriptors 
1 Constitutional 37 0.484 0.234 0.176 1.189 
Ms, nR10, RBF, nCL, 
nH, nTB, nR11, nR09, 
nAB, nCIC, nDB, Mp, 
AMW, nR07, nCIR, 
Mv, RBN, Ss, nSK, 
nX, Sp, Me, nR05 
2 Topological 225 0.806 0.649 0.585 0.798 
HNar, X4Av, piPC10, 
SPI, piPC09, D/Dr10, 
piPC07, D/Dr06, 
T(O..Cl), CIC2, X5v, 
T(Cl..Cl), Jhetp, 
piPC06, piPC03, 
MPC06, X2sol, 
SEige, X2Av, 
D/Dr11, D/Dr07 
3 
Molecular 
walk 
19 0.532 0.283 0.213 1.098 
MWC08, MWC06, 
SRW08, SRW05, 
SRW10, MWC05, 
MWC04, SRW04, 
MWC09, MWC01, 
MWC07, SRW07 
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No. Group name 
# of 
calculated 
descriptors 
R R
2
 R
2
adj. 
Standard 
Error of 
estimation 
Selected descriptors 
4 BCUT 64 0.781 0.609 0.521 0.857 
 BELm2, BELm3, 
BELe4, BEHe5, 
BEHv8, BELp1, 
BEHm4, BEHm8, 
BELv3, BEHv2, 
BELm5, BELv5, 
BEHm5, BELm1, 
BELe2, BELp3, 
BEHp4, BEHe4, 
BELp8, BELm8, 
BELe5, BEHv4, 
BEHe6, BELv7, 
BELm7 
5 
Galvez 
topological 
charge indices 
21 0.708 0.501 0.409 0.952 
JGI2, JGI6, JGT, 
JGI3, JGI4, JGI10, 
GGI6, GGI2, GGI8, 
GGI1, JGI1, JGI8, 
GGI3, GGI10, JGI9, 
GGI7, JGI7, JGI5, 
GGI4, GGI5, GGI9 
6 
2D 
autocorrelatio
ns 
96 0.729 0.532 0.495 0.880 
MATS4e, MATS1v, 
GATS6e, GATS7v, 
ATS4p, MATS5p, 
MATS5m, GATS8e, 
GATS7p, MATS7m 
7+8
+17 
Charge+ 
Aromaticity+
G16 
35 0.648 0.419 0.300 1.036 
dipole moment 
(Debyes), Hardness, 
TE1, Hydration 
Energy (kcal/mol), 
Qneg2, Log P, qpos, 
qneg, Mass (amu), 
Polarizability, LDip, 
Surface Area (Grid), 
Volume, Qmean, 
Refractivity, TE2, 
heat of formation 
(kcal/mol), PCWTe, 
electrophilicity, 
HOMO (eV), Q2, 
RPCG, softness 
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No. Group name 
# of 
calculated 
descriptors 
R R
2
 R
2
adj. 
Standard 
Error of 
estimation 
Selected descriptors 
9 
Randic 
molecular 
profiles 
41 0.367 0.135 0.073 1.19163 
DP20, SHP2, DP01, 
DP04, SP02, SP15, 
SP01, SP13, DP17 
10 Geometrical 31 0.539 0.290 0.129 1.15519 
 DELS, SPH, PJI3, 
G(N..N), TIE, SPAN, 
H3D, SPAM, SEig, 
MEcc, MAXDP, 
MAXDN, W3D, 
G(O..Cl), G(F..Cl), 
J3D, G(Cl..Cl), G2, 
FDI, ADDD, G1, 
AGDD, G(N..O), 
ASP, L/Bw 
11 RDF 150 0.658 0.433 0.372 0.98087 
RDF125m, 
RDF030m, 
RDF035m, RDF075v, 
RDF090e, RDF070u, 
RDF125v, RDF130e, 
RDF120v, RDF105m, 
RDF090m, RDF015u, 
RDF050v 
12 3D-MorSE 160 0.673 0.453 0.374 0.97902 
Mor10u, Mor15e, 
Mor04p, Mor22e, 
Mor28v, Mor31u, 
Mor02u, Mor32e, 
Mor11e, Mor05m, 
Mor10v, Mor11u, 
Mor15u, Mor10p, 
Mor19p, Mor12u, 
Mor08m 
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No. Group name 
# of 
calculated 
descriptors 
R R
2
 R
2
adj. 
Standard 
Error of 
estimation 
Selected descriptors 
13 WHIM 99 0.613 0.376 0.279 1.051 
L2v, G1v, P2m, G1e, 
L2p, L2e, Vv, Vp, Ve, 
E2s, Vu, L2u, Vm, 
L2m, Ds, E3m, Dm, 
G3s 
14 GETAWAY 196 0.784 0.615 0.544 0.836 
R8e+, R1p+, H5e, 
R4e+, R4u+, R4m+, 
H3u, HGM, HATS1e, 
R7m, ITH, R1m+, 
H5m, R6v+, HATS6p, 
H5u, HATSv, 
HATS2p, R8u, H6p, 
R8m 
15 Functional 24 0.694 0.481 0.385 0.970 
nCONR2, nN-N, 
nCONR2Ph, nC=NPh, 
nCrH2, nNR2, 
nCONHRPh, n#CH, 
nCs, nCaH, nCt, 
n=CHR, nPhX, nCaR, 
nRORPh, nCp, 
nCrHR, nC=N, 
nCONHR, nNHR, 
nHDon 
16 
Atom-centered 
fragments 
38 0.795 0.632 0.553 0.828 
C-005, C-043, C-027, 
N-068, N-071, H-050, 
C-003, C-031, C-040, 
C-001, C-008, H-054, 
C-028, C-021, O-059, 
N-075, C-026, C-006, 
N-073, H-051, O-060, 
H-047, C-024, C-016 
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 Performing the second MLR using SPSS, in which MLR applied on the groups of 
descriptors resulted from the first MLR together. 
Results of second MLR is summarized in table 3-2, where only the models having R
2
 
≥ 0.6 were taken to continue into the next step. So models 12- 24 which have R2 ≥ 0.6 
were taken for cross validation (leave one out and leave many out) [92]. 
 
 
 Table 3-2: MLR Models resulted from all the groups of descriptors together 
 
Model 
No. 
No. of 
descriptors 
R R
2
 R
2
adj. Selected descriptors 
12 12 0.787 0.620 0.583 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4 
13 13 0.803 0.645 0.607 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e 
14 14 0.815 0.665 0.626 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3 
15 15 0.828 0.686 0.647 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon 
16 16 0.842 0.709 0.670 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003 
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Model 
No. 
No. of 
descriptors 
R R
2
 R
2
adj. Selected descriptors 
17 17 0.851 0.725 0.685 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003, 
MATS4e 
18 18 0.862 0.742 0.703 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003, 
MATS4e, BEHm4 
19 19 0.875 0.765 0.727 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003, 
MATS4e, BEHm4, Hydration 
Energy (kcal/mol) 
20 20 0.886 0.784 0.747 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003, 
MATS4e, BEHm4, Hydration 
Energy (kcal/mol), G(O..Cl) 
21 21 0.893 0.797 0.760 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003, 
MATS4e, BEHm4, Hydration 
Energy (kcal/mol), G(O..Cl), 
electrophilicity 
22 22 0.897 0.805 0.767 
 JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003, 
MATS4e, BEHm4, Hydration 
Energy (kcal/mol), G(O..Cl), 
electrophilicity, Mor22e 
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Model 
No. 
No. of 
descriptors 
R R
2
 R
2
adj. Selected descriptors 
23 23 0.902 0.813 0.775 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003, 
MATS4e, BEHm4, Hydration 
Energy (kcal/mol), G(O..Cl), 
electrophilicity, Mor22e, 
Mor08m 
24 24 0.909 0.826 0.788 
JGI2, Mor10u, C-005, R8e+, 
nN-N, nR10, Mor19p, 
RDF035m, RDF030m, 
nCONHRPh, X4Av, BEHe4, 
G1e, BELm3, nHDon, C-003, 
MATS4e, BEHm4, Hydration 
Energy (kcal/mol), G(O..Cl), 
electrophilicity, Mor22e, 
Mor08m, Mor11e 
 
The below equation represents the best MLR model number 24; 
pIC50 = 32.804 (± 5.902) - 8.386 (±6.190) JGI2 - 0.159 (±0.122) Mor10u + 0.249 (± 
0.120) C-005 - 6.653 (±3.382) R8e
+
 - 2.222 (±0.258) nN-N + 0.661 (±0.192) nR10 
+ 0.537 (±0.191) Mor19p + 0.106 (±0.022) RDF035m - 0.043 (±0.031) RDF030m - 
1.288 (±0.348) nCONHRPh -205.791 (±27.444) X4Av - 12.548 (±1.485) BEHe4 - 
36.414 (±15.927) G1e + 8.988 (±1.817) BELm3 -0.106 (±0.0947) nHDon - 2.671 
(±0.382) C-003 - 4.090 (±0.913) MATS4e + 5.928 (±1.338) BEHm4 + 0.255 
(±0.057) Hydration Energy + 0.032 (±0.007) G(O..Cl) - 1.366 (±0.471) 
electrophilicity - 0.525 (±0.181) Mor22e - 0.360 (±0.102) Mor08m - 0.288 (±0.103) 
Mor11e. 
Where R=0.909, R
2
 = 0.826, R
2
adj =0.788, and the STD error of the estimate = 0.5700. 
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Each descriptor in model 24 equation is mentioned with brief description and its group in 
table 3-3. 
 
Table 3-3: Brief description of the descriptors in the best MLR model equation. 
 
Name   Description Block (group) 
JGI2 
Mean topological charge index of order 2 
Galvez topol. Charge 
indices 
Mor10u Signal 10 / unweighted 3D-MoRSE descriptors 
C-005 
CH3X 
Atom-centred 
fragments 
R8e+ R maximal autocorrelation of lag 8 / 
weighted by Sanderson electronegativity GETAWAY descriptors 
nN-N Number of N hydrazines Functional group counts 
nR10 Number of 10-membered rings Ring descriptors 
Mor19p Signal 19 / weighted by polarizability 3D-MoRSE descriptors 
RDF035m Radial Distribution Function - 035 / 
weighted by mass RDF descriptors 
RDF030m Radial Distribution Function - 030 / 
weighted by mass RDF descriptors 
nCONHRPh Number of secondary amides (aromatic) Functional group counts 
X4Av Average valence connectivity index of 
order 4 Connectivity indices 
BEHe4 Highest eigenvalue n. 4 of Burden matrix 
/ weighted by atomic Sanderson 
electronegativities BCUT 
G1e 1st component symmetry directional 
WHIM index / weighted by Sanderson 
electronegativity WHIM descriptors 
BELm3 Lowest eigenvalue n. 3 of Burden matrix 
/ weighted by atomic masses BCUT 
nHDon Number of donor atoms for H-bonds (N 
and O) Functional group counts 
C-003 
CHR3 
Atom-centred 
fragments 
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Name   Description Block (group) 
MATS4e Moran autocorrelation of lag 4 weighted 
by Sanderson electronegativity 2D autocorrelations 
BEHm4 Highest eigenvalue n. 4 of Burden matrix 
/ weighted by atomic masses BCUT 
Hydration Energy 
(kcal/mol) 
Hydration Energy (kcal/mol) 
G16-quantum-chemical 
G(O..Cl) Sum of geometrical distances between 
O..Cl Geometrical descriptors 
Electrophilicity Electrophilicity G16-quantum-chemical 
Mor22e Signal 22 / weighted by Sanderson 
electronegativity 3D-MoRSE descriptors 
Mor08m Signal 08 / weighted by mass 3D-MoRSE descriptors 
Mor11e Signal 11 / weighted by Sanderson 
electronegativity 3D-MoRSE descriptors 
 
 
Based on the equation of the best MLR model, the following descriptors have a 
positive effect on the compounds activity: 
C-005, nR10, Mor19p, RDF035m, BELm3, BEHm4, Hydration Energy, G(O..Cl). 
While the below descriptors have a negative effect on the compounds activity,   
 JGI2, Mor10u, R8e
+
, nN-N, RDF030m, nCONHRPh, X4Av, BEHe4, G1e, nHDon,   
C-003, MATS4e, electrophilicity, Mor22e, Mor08m, Mor11e. 
 
 Cross validation performed on the MLR resulted models (12-24), using MATLAB 
software. The results of cross validation LOO and LMO are summarized in table (3-4) 
and (3-5) respectively. Where:  PRESS (Predictive residual sum of squares) which 
also called SSE (Error sum of squares). PRESS is standard index to measure the 
accuracy of the model, SST (Total sum of squares), R
2
CV or Q
2
 (Cross validated 
correlation coefficient), SPRESS (uncertainty of prediction), PSE (Predictive Square 
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Errors) which also called RMSE (Root Mean Square Error), and RSEP (Relative 
Standard Error of Prediction). 
 
Table 3-4 and 3-5 show a good predictive power for models 19-24 because of having 
high R
2
CV and PRESS/SST less than 0.4. Thus, models 19-24 were chosen for ANN 
analysis.  
 
 
Table 3-4: LOO cross validation results. 
 
model No. desc. PRESS SPRESS SST R
2
CV PRESS/SST PSE RSEP 
12 12 87.824 0.845 125.942 0.302 0.697 0.803 11.004 
13 13 87.431 0.846 125.303 0.302 0.697 0.801 10.980 
14 14 78.757 0.806 132.741 0.406 0.593 0.760 10.421 
15 15 74.705 0.789 136.882 0.454 0.545 0.741 10.149 
16 16 68.680 0.759 142.558 0.518 0.481 0.710 9.731 
17 17 67.408 0.755 144.202 0.532 0.467 0.704 9.641 
18 18 63.928 0.739 147.714 0.567 0.432 0.685 9.389 
19 19 56.146 0.695 154.679 0.637 0.362 0.642 8.799 
20 20 54.708 0.689 156.560 0.650 0.349 0.634 8.685 
21 21 52.413 0.678 158.942 0.670 0.329 0.620 8.501 
22 22 50.644 0.669 160.676 0.684 0.315 0.610 8.356 
23 23 49.162 0.662 162.211 0.696 0.303 0.601 8.233 
24 24 46.108 0.644 165.143 0.720 0.279 0.5822 7.973 
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Table 3-5: LMO cross validation results. 
 
Model No. desc. PRESS                               
 
SPRESS SST  R
2
CV       PRESS/SST PSE  RSEP  
12 12 102.289 0.911 145.424 0.296 0.703 0.867 11.795 
13 13 95.909 0.886 152.582 0.371 0.628 0.839 11.421 
14 14 89.930 0.862 154.158 0.416 0.583 0.813 11.060 
15 15 84.282 0.838 157.975 0.466 0.533 0.787 10.707 
16 16 83.151 0.835 162.574 0.488 0.511 0.781 10.635 
17 17 82.525 0.836 172.536 0.521 0.478 0.779 10.595 
18 18 77.411 0.813 174.643 0.556 0.443 0.754 10.261 
19 19 69.566 0.774 177.321 0.607 0.392 0.715 9.727 
20 20 64.308 0.747 179.401 0.641 0.358 0.687 9.352 
21 21 62.574 0.740 189.644 0.67 0.33 0.678 9.225 
22 22 59.976 0.728 191.991 0.687 0.312 0.664 9.032 
23 23 58.036 0.719 195.521 0.703 0.296 0.653 8.885 
24 24 52.387 0.687 195.586 0.732 0.267 0.620 8.441 
 
 The PCA was performed to divide the molecules into training, validation, and prediction 
(test) sets. Performing PCA on the whole data of 136 compounds, 24 descriptors and 
plotting the first and second principals, first and third principals, and second and third 
principals. The data division into 60% training, 20% test and 20% validation, should be 
in equal manner in which picking one compound from each zone to each set. 
The first and second principals and first and third principals plots were having a 
condensed data towards the X axis, however second and third principals plot have the 
data distributed in a good way in comparison with the other plots. 
Therefore relying on the second and third principals plot, it shows compounds 13, 22 
and 86 as outliers (Figure 3-1). Although these three compounds don't differ structurally 
in comparison with other compounds. But they behave in a different manner, therefore 
these compounds removed from the data in the next analysis. And so the data divided 
after removing the outliers into 60% (81 compounds) training group, 20% (26 
compounds) of each test and validation groups. 
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Figure 3-1: Second and third principal components plot. 
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 First Artificial Neural Networks (ANN), Performed on the chosen models (19-24) from 
LOO and LMO validation. Apply the ANN on each model with 7 hidden nodes. 
The results of first ANN is in table 3-6, the table shows that model 24 has the highest 
correlation coefficient for the test set (0.850) indicating its high predictive power and 
the one after it is model 21. 
 
Figure 3-2 shows the relation of PRESS values for the training, test and validation sets 
versus model number. This figure shows that the minimum PRESS of the training set is 
obtained for model 21 the one after it is model 20. While the minimum PRESS of the 
test sets is obtained for model 24 the one after it is model 21 then 23.  
 
Figure 3-3 shows the relation of correlation coefficient (R) values for the training, test 
and validation sets versus model number. This figure shows that the highest (R) value of 
the training set is obtained for model 21 then 20. While the highest (R) value of the test 
set is obtained for model 24 then model 21 then model 23. 
 
Figure 3-4 shows the relation of R
2
CV (Cross validated correlation coefficient) values for 
the training, test and validation sets versus model number. This figure shows that the 
highest (R
2
CV) value of the training set is obtained for model 21 then 20. While the 
highest (R
2
CV) value of the test set is obtained for model 21 then model 24 then model 
23. 
Accordingly, models 20, 21, 23, and 24 were subjected for further analysis by 
optimizing the number of hidden nodes, because these models have the highest R, R
2
CV 
and low PRESS values for test set.
 65 
 
                   
     
      Table 3-6: Correlation Coefficient and Cross Validation Parameters for ANN Models 19-24. 
Mo.# hn nPCs R_tr           PRESS_tr       R
2
CV_tr R_test          PRESS_test        R
2
CV_test          R_val PRESS_val R
2
CV _val 
19 7 7 0.905 19.605 0.753 0.805 15.511 0.401 0.718 26.234 0.210 
20 7 7 0.927 15.319 0.824 0.812 15.064 0.437 0.726 26.259 0.298 
21 7 7 0.932 14.085 0.840 0.832 14.034 0.607 0.740 25.528 0.358 
22 7 6 0.911 18.292 0.789 0.802 15.934 0.335 0.686 28.443 -0.047 
23 7 6 0.906 19.118 0.783 0.818 14.526 0.502 0.655 30.734 -0.133 
24 7 6 0.909 18.701 0.785 0.850 12.206 0.578 0.685 28.852 0.108 
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Figure 3-2: Plots of ANN Predictive Residual Sum of Squares (PRESS) values for the 
training, test and validation sets versus model number. 
 
Figure 3-3: Plots of ANN correlation coefficient (R) values for the training, test and 
validation sets versus model number. 
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Figure 3-4: Plots of ANN R
2
CV (Cross validated correlation coefficient) values for the 
training, test and validation sets versus model number. 
 Second ANN performed on the chosen models 20, 21, 23, 24, each model with a range 
of hidden nodes starting from 5 to 20. The results are shown in tables; 3-7, 3-8, 3-9 and 
3-10 respectively. 
According to the results tables; model 20 with 10 hidden nodes, model 21 with 7 hidden 
nodes, model 23 with 5 hidden nodes, and model 24 with 7 hidden nodes were chosen 
as the best models with the optimal hidden nodes because they have high prediction 
power (R), minimum PRESS value of the test group, and minimum number of hidden 
nodes. 
 Table 3-11 summarize the correlation coefficients and cross validation parameters for 
the optimal number of hidden nodes for each one of the chosen models, where Models 
23 and 24 chosen as best models to continue to randomization test. 
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Table 3-7: Correlation Coefficients and Cross Validation Parameters of Number of Hidden Nodes for Model #20. 
 
 
 
 
hn nPCs R_tr    PRESS_tr R
2
CV _tr RSEP_tr R_test          PRESS_test        R
2
CV _test          RSEP_test       R_val PRESS_val R
2
CV _val RSEP_val 
5 7 0.903 19.757 0.768 6.694 0.842 13.437 0.483 9.496 0.807 20.161 0.471 12.207 
6 7 0.907 19.034 0.787 6.571 0.808 15.277 0.515 10.125 0.728 25.439 0.259 13.712 
7 7 0.927 15.319 0.82 5.895 0.812 15.064 0.437 10.054 0.726 26.259 0.299 13.931 
8 7 0.922 16.072 0.814 6.038 0.815 15.467 0.520 10.188 0.708 26.973 0.158 14.119 
9 7 0.912 18.143 0.784 6.415 0.807 15.290 0.416 10.129 0.671 29.785 -0.030 14.837 
10 7 0.938 13.007 0.859 5.432 0.847 13.384 0.483 9.477 0.736 26.058 0.361 13.877 
11 7 0.921 16.289 0.820 6.079 0.817 15.042 0.359 10.047 0.688 29.179 0.042 14.684 
12 7 0.908 18.927 0.774 6.552 0.807 15.419 0.366 10.172 0.669 30.706 -0.199 15.064 
13 7 0.903 20.615 0.739 6.838 0.804 15.704 0.517 10.266 0.679 29.911 0.081 14.868 
14 7 0.917 17.037 0.811 6.217 0.809 15.277 0.377 10.125 0.695 29.035 0.254 14.649 
15 7 0.922 16.162 0.812 6.055 0.818 15.358 0.614 10.152 0.678 32.198 0.174 15.426 
16 7 0.908 18.879 0.781 6.544 0.847 12.532 0.644 9.170 0.693 28.242 0.063 14.447 
17 7 0.913 17.872 0.793 6.367 0.817 14.673 0.464 9.923 0.722 27.241 0.338 14.189 
18 7 0.928 15.041 0.823 5.841 0.809 15.818 0.265 10.303 0.707 28.550 0.123 14.526 
19 7 0.909 18.727 0.783 6.518 0.801 16.211 0.315 10.429 0.748 24.144 0.293 13.358 
20 7 0.926 15.574 0.812 5.944 0.811 15.109 0.469 10.069 0.757 24.439 0.328 13.439 
 69 
 
 
Table 3-8: Correlation Coefficients and Cross Validation Parameters of Number of Hidden Nodes for Model #21. 
 
hn nPCs R_tr    PRESS_tr R
2
CV _tr RSEP_tr R_test          PRESS_test        R
2
CV _test          RSEP_test       R_val PRESS_val R
2
CV _val RSEP_val 
5 7 0.902 20.061 0.773 6.746 0.839 14.090 0.498 9.723 0.756 25.788 0.291 13.81 
6 7 0.903 19.896 0.766 6.718 0.813 14.874 0.494 9.991 0.694 28.482 0.185 14.509 
7 7 0.932 14.085 0.840 5.652 0.832 14.034 0.607 9.704 0.739 25.528 0.358 13.736 
8 7 0.901 20.916 0.716 6.888 0.829 14.141 0.431 9.742 0.735 26.559 0.139 14.010 
9 7 0.901 20.259 0.763 6.779 0.807 16.340 0.471 10.472 0.729 27.239 0.187 14.188 
10 7 0.912 18.574 0.759 6.491 0.838 13.134 0.539 9.388 0.672 29.733 -0.314 14.824 
11 7 0.926 15.351 0.834 5.901 0.811 16.364 0.579 10.479 0.732 26.434 0.124 13.98 
12 7 0.917 17.107 0.807 6.229 0.800 17.048 0.571 10.696 0.686 30.444 0.244 14.999 
13 7 0.923 15.824 0.823 5.991 0.810 15.321 0.368 10.14 0.716 27.400 0.159 14.230 
14 7 0.900 20.319 0.768 6.789 0.829 13.876 0.596 9.649 0.654 32.595 0.029 15.521 
15 7 0.905 19.758 0.746 6.695 0.813 15.798 0.241 10.296 0.669 32.587 0.106 15.519 
16 7 0.901 20.166 0.769 6.763 0.804 15.683 0.431 10.259 0.728 25.551 0.099 13.742 
17 7 0.919 17.195 0.778 6.245 0.817 14.738 0.441 9.945 0.689 29.422 0.077 14.746 
18 7 0.929 14.557 0.841 5.746 0.856 11.967 0.544 8.961 0.724 25.729 0.1445 13.789 
19 7 0.908 18.974 0.801 6.560 0.804 16.337 0.561 10.470 0.704 29.388 0.205 14.737 
20 7 0.910 18.534 0.781 6.484 0.820 14.726 0.361 9.941 0.716 26.183 0.100 13.911 
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Table 3-9: Correlation Coefficients and Cross Validation Parameters of Number of Hidden Nodes for Model #23. 
 
hn nPCs R_tr    PRESS_tr R
2
CV _tr RSEP_tr R_test          PRESS_test        R
2
CV _test          RSEP_test       R_val PRESS_val R
2
CV _val RSEP_val 
5 6 0.905 19.511 0.769 6.653 0.832 14.019 0.468 9.699 0.680 30.185 0.183 14.936 
6 6 0.909 18.783 0.789 6.527 0.804 16.982 -0.017 10.675 0.679 29.667 0.000 14.807 
7 6 0.906 19.118 0.782 6.585 0.818 14.526 0.502 9.873 0.655 30.734 -0.132 15.071 
8 6 0.928 15.063 0.824 5.845 0.812 15.349 0.445 10.149 0.722 26.162 0.266 13.905 
9 6 0.931 14.482 0.833 5.731 0.803 15.675 0.372 10.256 0.785 20.716 0.435 12.373 
10 6 0.903 19.740 0.781 6.692 0.801 16.609 0.137 10.558 0.714 27.067 0.227 14.143 
11 6 0.908 19.090 0.759 6.580 0.800 15.915 0.376 10.334 0.618 34.389 -0.129 15.942 
12 6 0.910 18.548 0.772 6.486 0.831 13.888 0.424 9.654 0.767 22.356 0.189 12.854 
13 6 0.910 18.485 0.779 6.475 0.849 12.798 0.518 9.267 0.662 30.394 -0.05 14.988 
14 6 0.917 17.426 0.783 6.287 0.801 16.244 0.362 10.441 0.625 34.708 -0.458 16.016 
15 6 0.901 20.441 0.775 6.809 0.818 15.041 0.603 10.047 0.704 27.055 0.038 14.140 
16 6 0.939 12.585 0.862 5.343 0.871 10.868 0.603 8.540 0.673 31.389 0.123 15.230 
17 6 0.902 19.957 0.769 6.728 0.803 16.809 0.075 10.621 0.659 31.511 -0.273 15.260 
18 6 0.926 15.324 0.841 5.896 0.804 16.482 0.571 10.517 0.654 33.083 0.179 15.636 
19 6 0.918 16.946 0.815 6.199 0.802 16.063 0.443 10.382 0.642 33.224 0.045 15.669 
20 6 0.935 13.616 0.851 5.557 0.811 15.441 0.423 10.179 0.612 34.747 -0.115 16.025 
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Table 3-10: Correlation Coefficients and Cross Validation Parameters of Number of Hidden Nodes for Model #24. 
 
hn nPCs R_tr    PRESS_tr R
2
CV _tr RSEP_tr R_test          PRESS_test        R
2
CV _test          RSEP_test       R_val PRESS_val R
2
CV _val RSEP_val 
5 6 0.905 19.461 0.773 6.644 0.836 14.17 0.447 9.751 0.733 24.915 0.188 13.569 
6 6 0.916 17.311 0.809 6.266 0.864 13.813 0.171 9.628 0.728 26.033 -0.108 13.871 
7 6 0.909 18.701 0.785 6.513 0.850 12.206 0.578 9.050 0.685 28.852 0.108 14.602 
8 6 0.939 12.766 0.861 5.381 0.802 15.810 0.518 10.30 0.659 32.616 0.076 15.526 
9 6 0.901 20.272 0.763 6.781 0.815 15.077 0.346 10.059 0.626 32.803 -0.28 15.570 
10 6 0.904 19.657 0.779 6.678 0.816 14.657 0.487 9.918 0.643 32.636 -0.042 15.530 
11 6 0.918 17.379 0.783 6.279 0.831 14.127 0.418 9.737 0.655 33.441 -0.359 15.720 
12 6 0.901 20.287 0.755 6.784 0.847 12.705 0.572 9.233 0.644 32.928 0.046 15.599 
13 6 0.919 16.803 0.795 6.174 0.850 13.344 0.364 9.463 0.648 31.485 -0.169 15.254 
14 6 0.931 14.464 0.836 5.728 0.846 12.668 0.626 9.219 0.726 26.054 0.185 13.876 
15 6 0.919 16.688 0.808 6.153 0.837 13.353 0.554 9.466 0.703 28.696 -0.469 14.563 
16 6 0.905 19.644 0.757 6.675 0.814 15.279 0.321 10.128 0.673 29.618 -0.385 14.795 
17 6 0.912 18.087 0.782 6.405 0.841 13.534 0.413 9.530 0.773 21.857 0.231 12.709 
18 6 0.939 12.555 0.873 5.337 0.823 14.911 0.415 10.002 0.691 29.843 -0.054 14.851 
19 6 0.938 12.968 0.853 5.424 0.810 15.186 0.459 10.095 0.612 35.254 -0.257 16.141 
20 6 0.942 12.428 0.881 5.309 0.839 13.094 0.621 9.374 0.647 33.343 -0.063 15.698 
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Table 3-11: Summary of the Correlation Coefficients and Cross Validation Parameters of the Optimal Number of Hidden Nodes of Each Model 
Mo. 
# 
hn nPCs R_tr  PRESS_tr  R
2
CV _tr RSEP_tr R_test          PRESS_test        R
2
CV _test          RSEP_test       R_val PRESS_val R
2
CV _val RSEP_val 
20 10 7 0.938 13.007 0.859 5.432 0.847 13.384 0.482 9.477 0.736 26.058 0.361 13.877 
21 7 7 0.932 14.085 0.84 5.652 0.832 14.034 0.607 9.704 0.739 25.528 0.358 13.736 
23 5 6 0.905 19.511 0.769 6.653 0.832 14.019 0.468 9.699 0.68 30.185 0.183 14.936 
24 7 6 0.909 18.701 0.785 6.513 0.85 12.206 0.578 9.05 0.685 28.852 0.108 14.602 
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 ANN resulted model validation through randomization test, to ensure that the ANN 
resulted model is not due to a chance. Results of model 23 with 5 Hn and model 24 with 
7 hn are shown in tables 3-12 and 3-13 respectively. These tables show that the 
Correlation coefficients obtained by chance are low in general while PRESS values are 
high. This indicates that models 23 and 24 which obtained from PCA-ANN are better 
than those obtained by chance and they are not due to chance. 
 
Figures 3-5 and 3-6 show regressions between observed and predicted activity as well 
as their residuals for the training, validation, and test sets for these two models.  
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Table 3-12: Chance Correlation of Model 23 with 5 Hidden Nodes 
 
Trial No. nPCs           R_tr PRESS_tr R
2
CV _tr R_test PRESS_test  R
2
CV _test  R_val  PRESS_val  R
2
CV _val  
1 6 0.155 186.679 -15.323 -0.248 11.546 -90.928 0.636 5.875 -32.209 
2 6 0.151 199.228 -4.803 0.261 12.329 -219.405 -0.223 14.905 -82.514 
3 6 0.065 204.245 -8.594 -0.37 11.879 -109.392 0.117 6.576 -46.601 
4 6 0.130 189.856 -13.569 -0.348 11.517 -842.777 -0.785 9.682 -72.311 
5 6 0.105 191.083 -18.737 -0.138 11.052 -377.239 -0.748 7.378 -317.342 
6 6 -0.245 214.801 -31.479 0.311 10.846 -591.173 0.582 5.568 -728.723 
7 6 0.116 374.285 -5.095 0.024 11.339 -39.912 -0.783 8.307 -11.770 
8 6 0.037 213.845 -6.671 -0.027 11.011 -307.729 -0.630 6.815 -221.652 
9 6 0.248 180.384 -6.080 0.198 15.225 -389.789 -0.6916 19.562 -106.548 
10 6 -0.043 219.869 -7.936 0.358 9.702 -5.176 0.964 3.538 -8.333 
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Table 3-13: Chance Correlation of Model 24 with 7 Hidden Nodes  
 
Trial No. nPCs           R_tr PRESS_tr R
2
CV _tr R_test PRESS_test  R
2
CV _test  R_val  PRESS_val  R
2
CV _val  
1 6 0.224 183.467 -6.709 0.189 12.548 -270.109 -0.257 11.440 -69.747 
2 6 0.292 175.064 -10.017 -0.454 14.204 -1085.815 -0.108 13.204 -292.240 
3 6 0.077 195.875 -12.219 -0.358 13.879 -63.759 0.354 3.999 -23.686 
4 6 -0.277 229.782 -16.547 -0.381 13.326 -502.793 0.652 3.759 -51.454 
5 6 0.076 200.859 -13.897 -0.345 11.929 -301.221 -0.808 11.332 -74.118 
6 6 0.061 223.055 -4.677 -0.161 11.580 -19590.4 0.639 9.807 -1928.422 
7 6 -0.173 283.432 -3.888 0.365 10.382 -27.965 -0.728 19.075 -8.395 
8 6 0.047 257.630 -2.261 -0.454 13.189 -35.861 0.699 3.071 -6.059 
9 6 -0.179 268.564 -4.842 -0.428 16.450 -19.304 0.443 3.942 -5.322 
10 6 0.167 203.664 -3.476 0.009 11.528 -367.780 -0.692 4.978 -832.566 
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Figure 3-5: Plot of the predicted activity against observed one as well as their residues for 
model 23 using 5 hidden nodes. Training set, validation set, and external test 
set. 
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Figure 3-6: Plot of the predicted activity against observed one as well as their residues for 
model 24 using 7 hidden nodes. Training set, validation set, and external test 
set. 
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12
P
r
e
d
ic
t
e
d
 a
c
t
iv
it
y
Observed activity   
Test Set (Model 24)
 78 
 
The following conditions proposed by Golbraikh and Tropsha [92] were applied to 
conclude that the QSAR model has acceptable prediction power if: 
     (1) R
2
CV> 0.5 
     (2) R
2
 > 0.6 
     (3) (R
2
 - R
2
0)/ R
2
 < 0.1 and 0.85 < k < 1.15 
           Or 
          (R
2
 – R'20)/R2 < 0.1 and 0.85 < k' < 1.15 
 
where R
2
0 and R'
2
0 are the coefficients of determination characterizing linear regression 
with Y-intercept set at zero, the first associated with observed vs. predicted values, the 
second related to predicted vs. observed values; k and k' are the slopes of the regression 
lines forced through zero, relating observed vs. predicted and predicted vs. observed 
values. 
(4) | R
2
0 - R'
2
0 | < 0.3 
 
Alternatively, the parameter R
2
m (R
2
* (1 - (R
2
- R
2
0)
1/2
)) can be used. This parameter 
penalizes a model for large differences between observed and predicted values, was also 
calculated. R
2
m should be larger than 0.5 for a good external prediction.  
If a model shows good statistical performance for all these criteria, on both the training and 
the test sets, its reliability and robustness are high. 
Model 24 validated according to these criteria, and shows to have acceptable prediction 
power. 
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Structure-Activity Relationships of the Dataset: 
 Compounds 1 to 16 in table 2-1, SAR [86]: 
1- Position 3: 
The introduction of substituents in position 3 of the quinoline nucleus (Compound 4) 
increased the TSPO affinity in variable degree depending on the stereoelectronic 
properties of the substituent involved.  
The introduction of a methyl group produced an affinity enhancement of about an 
order of magnitude (compare 8 with 4), while an affinity increase of about 2 orders of 
magnitude was observed when a chloromethyl substituent was involved (compare 13 
with 4). The introduction of a hydroxymethyl or differently substituted aminomethyl 
groups (compounds 14,15) had less dramatic effects on TSPO affinity, and the 
comparison of the affinities shown by 4,8,9-15 suggests that the presence in 3-
position of substituents showing a wide range of stereoelectronic properties is 
compatible with a productive binding to TSPO.  
2- Position 2: 
Favorable effect of the introduction of a fluorine atom in position 2 of the pendent 
phenyl group (compare 10 vs. 8). 
 
3- Tolerance showed by the receptor in accommodating the second benzyl group on the 
amide nitrogen (compare 11 vs. 8). 
 
4- Slight superiority of the quinoline bicyclic system with respect to naphthalene (4 vs. 2 
and 8 vs. 6).  
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 Compounds 17 to 53 in table 2-1, SAR [87]: 
These findings are consistent with suggestions from QSAR analysis on the 2 
phenylimidazo[1,2-a]pyridine derivatives which suggested that a four carbon chain is the 
optimum length for the alkyl substitution on the carboxamide nitrogen. 
 
 Compounds 80 to 91 in table 2-1, SAR [89]: 
1- Comparison of the results obtained with compounds 80 and 86 confirms the previously 
observed difference in affinity between secondary and tertiary amides. In fact, 
secondary amide 86 shows a significantly lower TSPO affinity when compared to its N-
methylated counterpart 80.  
 
2- The comparison of the most potent compounds 80, 81 with 85, 87 demonstrates the 
importance of a lipophilic substituent in para-position of the amide phenyl.  
 
- The replacement of the amide phenyl group of compound 85 with the benzyl of 82 
appears to be well tolerated by TSPO, whereas the same substitution with a 
propargyl moiety is not accepted equally well (compare 88 vs 85). 
- The removal of the lipophilic chlorine atom in the pendant phenyl ring of the most 
active compounds 80, 81 leads to a decrease in TSPO affinity of about one order of 
magnitude (compounds 89, 90). 
- The transformation of the amide carbonyl of 80 into the methylene group of 91 
produces a dramatic decrease (2600 times) in the receptor affinity.  
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 Compounds 92 to 135 in table 2-1, SAR [49]: 
Compounds 92-116 confirm the essential role of the carbonyl function as the primary 
pharmacophoric element, and the importance of the role of both the amide substituents and 
the pendant phenyl ring for which a dispersive nature of the interactions with TSPO 
binding site. 
Compounds 117-135 show that the replacement of the ester function of 121 with a 
secondary (130) or tertiary amides (125- 127) affords compounds with similar micromolar 
range affinities, when compared with ester 121.  
 
In addition, the environment of the carbonyl amide seems to be relatively sensitive to steric 
hindrance since the increase in size of the amide substituents results in a progressive 
decrease in affinity (compare compounds 126-129 with 125).  
However suitably oriented lipophilic amide group plays a more substantial role and 
contributes to the binding strength much more than the one in the 3-position of the 
quinoline nucleus of 125-131. Taken together, these results suggest that the lipophilic 
amide groups in 3-position of the quinolone nucleus of compounds 125-131 occupy a 
receptor area different from the one occupied by the lipophilic amide groups of the high 
affinity TSPO ligands. 
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 Suggestion of new chemical structure with better activity than the available ones 
According to the previous SAR, and based on MLR model, the QSAR for TSPO ligand 
should have: 
1- Less number of N hydrazine groups (nN-N). 
2- Less number of secondary amides (aromatic) (nCONHRPh). 
3- Less number of donor atoms for H-bonds (N and O). 
4- Less number of CHR3 groups. 
5- Less Electrophilicity is required. 
6- More CH3X groups is useful. 
7- Increase number of 10-membered rings is useful. 
 
Below suggested compound as TSPO ligand: 
N
N
O
Cl
 
 
According to model 24 equation, the PIC50 of the suggested compound is range between 
20.7 – 31.9. Where the PIC50 of all the compounds used as dataset in this study was 
ranging between 4.6 – 9.8. 
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The suggested compound apply Lipinski rule of 5 with molecular weight less than 500, log 
P less than 5, no more than 5 hydrogen bond donors and no more than 10 hydrogen bond 
acceptors. 
 
Comparison with previous QSAR studies: 
There are seven Quantitative structure-activity relationship (QSAR) studies performed on 
TSPO ligands for different purposes, however only few of the studies performed on 
compounds of this study;  
 A linear regression analysis on pCI50 values for compounds 17 to 53 listed in table  
2-1   showed a good correlation (R
2
 = 0.870) [87]. 
 
  Study on compounds which have serial numbers from 17 to 39 listed in table 2-1.  
          was  performed by Kunal Roy, Toropov and Raska in 2006, which achevied a 
QSAR modeling of peripheral Versus Central Benzodiazepine Receptor Binding 
Affinity of 37 compounds 2-Phenylimidazo[1,2-a] pyridineacetamides using 
Optimal Descriptors Calculated with SMILES (Simplified Molecular Input Line 
Entry System) [93]. The results indicate promising potential of the optimization of 
correlation weights based on SMILES notation in modeling studies. 
 
  A quantitative structure-affinity relationships (QSAR) study performed on 
compounds 92 to 116 listed in table 2-1. Through comparison of the van der Waals 
volumes of the different ligands [49].  
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Other QSAR studies on TSPO ligands: 
 3D interaction model of endogenous and synthetic peripheral benzodiazepine 
receptor ligands was developed. Two lipophilic regions and one electrostatic 
interaction site are essential features for high affinity ligand binding, while a further 
lipophilic region plays an important modulator role. A comparative molecular field 
analysis, performed over 130 PBR ligands by means of the GRID/GOLPE 
methodology, led to a PLS model with both high fitting and predictive values 
(r
2
 = 0.898, Q
2
 = 0.761). The outcome from the 3D QSAR model and the GRID 
interaction fields computed on the putative endogenous PBR ligands DBI 
(Diazepam Binding Inhibitor) and TTN (Tetracontatetraneuropeptide) was used to 
identify the amino acids most probably involved in PBR binding. Three amino 
acids, bearing lipophilic side chains, were detected in DBI (Phe49, Leu47 and 
Met46) and in TTN (Phe33, Leu31 and Met30) as likely residues underlying 
receptor binding [94]. 
 
 Kunal and Sengupta in 2002 performed QSAR study for the binding affinities of 31 
compounds of [2-phenylimidazo[1,2-a]pyridin derivatives with central 
benzodiazepine and peripheral benzodiazepine (TSPO) receptors using physico-
chemical parameters. Attempt has been made to explore the structural and/or 
physico-chemical requirements of the compounds that are responsible for the 
selective action against peripheral benzodiazepine receptors over central ones [95].  
 
 Dalai, Leonard & Kunal [96] performed a QSAR for TSPO binding affinity in 2006, 
with 35 compounds of 2-phenlpyrazolo(1,5-a)pyrimidin-3-yl-acetamides using 
topological and physicochemical descriptors and resulted with sex models with 
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average R
2
=0.7.  The calculated hydrophobicity, logPcalc, shows a parabolic relation 
with the TSPO receptor binding affinity, which suggests that the binding affinity 
increases with the increase in the partition coefficient of the compounds until it 
reaches the critical value after which the affinity decreases. The range of the 
optimum values of logPcalc is between 5.423-5.819 as found from different equations. 
 
 Roy Kunal and Dalai performed a QSAR study in 2007 to explore the structural and 
physicochemical requirements of ligands N, N-dialkyl-2-phenylindol-3-yl-
glyoxylamides for binding with peripheral benzodiazepine receptor (TSPO) by using 
27 compounds. The calculated partition coefficient values show parabolic relations 
with the TSPO binding affinity, suggesting that the binding affinity increases with 
increase in the partition coefficient of the compounds until it reaches the critical 
value after which the affinity decreases. The critical value of logP is within range of 
6.052-6.410 [97].  
 
The disadvantage of the previous QSAR studies on TSPO ligand was that the number of 
used data set is small (e.g. 29 or 37 etc.) and thus affect the real prediction power of the 
resulted models. While in the current study 136 compound is used. Also all the previous 
QSAR studies performed to study certain group of descriptors (properties) such as: 
studying the physico-chemical parameters or the partition coefficient effect on the 
compounds activity. While in the current study all the possible properties were calculated 
for all the compounds and treated to build a predictive MLR model. .  
Also the methods used in the current study are MLR and PC-ANN, while in the previous 
studies either MLR alone or other methods which are having less powerful and prediction 
capabilities.  
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CONCLUSIONS: 
 
A quantitative-structural activity relationship analysis has been conducted on the activity 
of a set of 136 ligand for Translocator protein (TSPO), by using MLR and principal 
component-artificial neural networks (PC-ANN) modeling methods, where the strength 
and the predictive performance of the proposed models was verified using internal (cross-
validation and Y-scrambling). 
 
The results obtained by MLR was a number of models (Models 12- 24) which have a good 
predictive power (R
2
) > 0.6 , the best model was model number 24 which includes 24 
descriptors, and resulted with R= 0.909, R
2
=.826, and R
2
adj.= 0.788.  
Cross Validation LOO and LMO were performed on the resulted MLR models, models 19-
24 showed a good predictive power because of having high R
2
CV and PRESS/SST less than 
0.4. Thus, models 19-24 were chosen for ANN analysis.  
PCA performed to divide the data into three data sets, then the ANN performed on the 
chosen models (19-24) from LOO and LMO validation.  
The results shows that model 24 has the highest correlation coefficient for the test set 
(0.85016) indicating its high predictive power. While also there are other good predictive 
models (As model # 20, 21, 23), which chosen to continue ANN to find the optimal 
number of hidden nodes for each one of these models  
 
According to the results; model 20 with 10 hidden nodes, model 21 with 7 hidden nodes, 
model 23 with 5 hidden nodes, and model 24 with 7 hidden nodes were chosen as the best 
models with the optimal hidden nodes because they have high prediction power (R), 
minimum PRESS value of the test group, and minimum number of hidden nodes. 
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ANN resulted model were validated through randomization test, then the conditions 
proposed by Golbraikh and Tropsha were applied to conclude that the QSAR models have 
acceptable prediction power or not. However the best ANN model with a good predictive 
power was model #24. 
A new suggested compound with predicted PIC50 ranging between 20.7 – 31.9. 
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  ) NNA-CPو  RLM( تيدراسة العلاقة الكمية بين الفاعمية والصيغة البنائية باستخدام طريق
 )OPST( rotacolsnarTلها فعالية عمى بروتين  لبعض المركبات التي 
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مركب وصيغها البنائية عمى بروتين  136فعالية يتناول موضوع هذا البحث دراسة العلاقة الكمية بين 
)  RLMباستخدام الانحدار الخطي المتعدد (  RASQ. وقد وضعت نماذج rotacolsnarTيسمى 
) كطريقة غير  NNA -CPكطريقة خطية . بينما تم استخدام الشبكات العصبية الاصطناعية ( 
رة تنبؤ جيدة . النماذج التي نتجت عن النتائج التي تم الحصول عميها هي نماذج ذات قدخطية .
وكان الافضل  21-16هم النماذج من  6.0التي حصمت عمى معامل ارتباط اعمى من  و RLM
، وتم التحقق من قدرة النماذج عمى التنبؤ عن 0.0..مع معامل ارتباط يساوي  21نموذج رقم  بينها
ج، ثم تم توزيع المركبات الى افضل نتائ 21-06واظهرت النماذج  OMLو   OOLطريق استخدام 
 NNAفي  21-06استخدام النماذج تم . و ACPثلاث مجموعات عن طريق 
 )tset noitazimodnar(باستخدام  NNAتم التحقق من قوة وأداء كل النماذج المقترحة من من ثم و 
هو  21، وقد وجد ان النموذج رقم ahsporT و   hkiarbloGاقترحاها  يالظروف التوتطبيق 
 .238.0معامل ارتباط  فضل معالا
 
 
